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CHAPTER ONE: 
OVERVIEW AND HYPOTHESES 
Synucleinopathies are a group of neurodegenerative diseases associated with the 
intracellular accumulation of insoluble, pathological alpha-synuclein (α-syn) [1]. Although the 
exact cause of why α-syn becomes misfolded and begins to aggregate is unclear, the process is 
associated with neurotoxicity, eventually resulting in cell death [2-4]. Research indicates that α-
syn behaves in a prion-like fashion; meaning native α-syn is capable of misfolding, and can self-
propagate by inducing further misfolding, as well as, be transfered from cell-to-cell, resulting in 
the spread of pathology [5-7]. While the exact mechanism associated with the pathological 
transmission of α-syn has yet to be identified, recent evidence suggests that α-syn is secreted 
into the extracellular environment from cells utilizing an unconventional secretory mechanism 
[8, 9]. Furthermore, dysregulation of this mechanism can increase the secretion of pathological 
α-syn, including exosome associated α-syn [8, 9]. The secretion this exosome associated α-syn is 
particularly important as it has been shown to be readily taken up into recipient cells, where it is 
capable of causing further aggregation, neurotoxicity, and cell death [7-8, 10]. 
The first goal of this thesis was to examine how dysregulation of autophagy influenced 
the unconventional secretion of our novel α-syn dual-split protein model (described in greater 
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detail in Chapter 4). This unique model measures the luciferase intensity of complemented dual-
split protein constructs, allowing for the measurement of non-monomeric α-syn variants which 
are associated with α-syn aggregation and synucleinopathy disease pathology.  Current research 
suggests that unconventional secretion is dependent on the upregulation of autophagy, and that 
inhibiting the formation of the autophagophore, the precursor to the fully developed 
autophagosome, prevents this process [9]. Additionally, in a study conducted by Ejlerskov P et 
al. in 2013, they demonstrated that α-syn secretion can be increased by preventing the fusion of 
the autophagosome with the lysosome [9]. They hypothesized that this inhibition of lysosome 
and autophagosome fusion was increasing α-syn secretion due to the cell’s attempt to clear the 
accumulating undegraded autophagic cargo [9]. Based on the observations reported Ejlerskov 
and others, we hypothesized that if the formation of the autophagophore is an essential 
component to α-syn secretion then inhibiting its formation will result in decreased secretion of 
α-syn [9]. However, if autophagy is inhibited by preventing the fusion of the autophagosome 
with the lysosome, then an increase in α-syn secretion will still occur due to the cell’s attempt to 
clear the accumulating undegraded cargo within the autophagosomes, consistent with 
Ejlerskov’s hypothesis. Furthermore, because inhibition of proteasome activity and 
mitochondrial function cause an upregulation in autophagic activity [214-216, 221, 234], we 
hypothesized that the inhibition of either of the proteasome or the mitochondria will increase 
the secretion of α-syn.  
The second goal of this thesis was to develop a methodology that allowed for the 
analysis of extracellular vesicles, including exosomes on a single vesicle basis. The creation of 
methodologies to better study exosomes is of paramount importance as increasing evidence 
indicates that exosomes play a role in the progression of a variety of diseases [55, 56]. Included 
among these, are synucleinopathies, as misfolded, oligomeric species of α-syn are capable of 
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spreading cellular disease pathology from cell-to-cell [9]. Furthermore, because increasing 
evidence suggests that exosomes are not a homogenous population, the ability to isolate 
individual exosomes provides an opportunity to identify specific population subsets [55, 56]. In 
this thesis, we explain how our methodology is capable of analyzing single extracellular vesicles 
through the use of microscopy and imaging analysis techniques allowing for the identification of 
extracellular vesicle based on protein co-localization analysis. We then validated our 
methodology by showing what extracellular vesicles associated with exogenously added 
sonicated preformed fibrillar α-syn based on their co-localization with canonically accepted 
exosomal markers. 
In this next chapter, a review of the literature is provided to first acquaint the reader 
with synucleinopathies and the protein α-syn.  As the chapter progresses, an explanation of 
unconventional secretion via autophagy will be provided, including what is currently known that 
distinguishes secretory and degradative mechanisms.  Afterwards, a review of how this 
unconventional secretion affects the release of α-syn associated exosomes and how autophagic 
mechanisms can further influence this process. Finally, we will review the proteasome and 
briefly look at its intersecting role in both synucleinopathies and autophagy, including the 
clearance of mitochondria. 
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CHAPTER TWO: 
REVIEW OF THE LITERATURE 
Synucleinopathies 
Synucleinopathies are a group of neurodegenerative diseases that are characterized by 
their abnormal intracellular accumulation of the insoluble, aggregated protein deposits referred 
to as Lewy bodies (LBs) of which misfolded α-syn is the primary protein component [1, 7, 11, 
18]. Three major types of Synucleinopathies exist: Multiple systems atrophy (MSA), Dementia 
with Lewy bodies (DLB), and Parkinson’s disease (PD) [11]. 
 Motor dysfunction is central to PD symptoms which are collectively referred to as 
Parkinsonisms. These symptoms include bradykinesia, resting tremors, rigid mobility and 
instable posture [12-13].   While individuals with DLB also develop parkinsonisms, they also 
show classic dementia symptoms such as short-term memory loss, cognitive impairment, 
hallucinations, and emotional instability [14].  
MSA can be classified into two categories, cerebellar ataxia (MSA-C) or parkinsonism 
(MSA-P). The classifications depend on α-syn distribution, phenotypic manifestation, and 
pattern of spread [15-16]. Individuals with MSA-C manifest with disrupted gait and classic ataxia, 
while individuals with MSA-P have the classical Parkinsonisms previously described [15-16].  
Both categories of MSA also show autonomic dysfunction in addition to the previously stated 
symptoms [15-16].    
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The localized accumulation of α-syn within the brain regions of the central nervous 
systems (CNS) varies among these diseases [15-17]. However, the dopaminergic neurons within 
 the brain regions of the substantia nigra and basal ganglia are affected in all cases of 
synucleinopathies [17]. Why these regions of the CNS are specifically affected among 
synucleinopathies is not well understood [17, 20].  
Lewy Bodies and Alpha-Synuclein. 
In both familial and idiopathic cases of synucleinopathies the formation of intracellular, 
proteinaceous inclusions, known as the Lewy Body (LB) occurs [1, 18-19]. The LB is the 
histopathological hallmark of synucleinopathies, of which the primary protein is composed of 
aggregated α-syn [1, 18-19]. This aggregated α-syn is misfolded and contains a variety of higher 
order oligomerized structures that are post-translationally modified [20-22, 242]. The most 
abundantly observed among these modifications are the additions of phosphorylations and 
ubiquitinations [20-22, 242]. Furthermore, LBs are resistant to proteinase K digestion [244]. 
While the formation of these LBs was once thought to cause cellular toxicity eventually 
resulting in cell death, this initial idea has since become challenged [242]. Current, prevailing 
theories suggest that sequestration of α-syn, resulting in the formations of LBs, is a protective 
mechanism [242]. This process occurs as a result of the cell’s inability to degrade α-syn 
aggregates and that by collectively isolating these aggregates within a single structure, the cell 
can better concentrate its degradative efforts to a single location [242]. As a result of these 
previously stated findings, it is believed that a pathogenic variant of α-syn exists and its 
accumulation within the cell is responsible for pathology thus resulting in the diseased state.  
Alpha-Synuclein 
The protein, α-syn, is 140 amino acids and is found predominantly within the central 
nervous system (CNS) but is also located within other tissues including the kidneys and red 
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blood cells [43-45]. α-syn gets its name from its localization within neurons, the synapse and the 
nucleus [46].  
Native α-syn is generally believed to be found as a soluble monomer however some 
evidence has shown that it is capable of forming a tetrameric, alpha-helix [27-28]. In addition, it 
has been reported that a small amount of equilibrium between an oligomeric and fibrillar 
configurations occurs under normal conditions [27-28].  
Furthermore, while generally found unfolded, α-syn is also capable of forming an 
amphipathic alpha-helix upon its association with a lipid membrane which is thought to be 
important for α-syn’s cellular function as a SNARE protein [2, 41]. The formation of this alpha-
helix is achieved by the amino acid residues found within the conserved KTKEGV sequence 
[243].  This KTKEGV sequence is shared among the other members of the synuclein family, 
which totals in three with the addition of beta-synuclein and gamma-synuclein [43]. While these 
others synucleins share homology with the α-syn, only α-syn has been shown to be pathogenic 
[43]. 
While α-syn’s exact function in synaptic vesicle trafficking as a SNARE protein has yet to 
be identified, genetic studies indicate that α-syn plays a role catecholaminergic 
neurotransmitter vesicle release, as α-syn knock-out mice display abnormal transmission within 
their dopaminergic neurons [2, 41]. However, this knock-out is not embryonic lethal and 
phenotypically these mice are relatively normal and display minimal neurological behavioral 
differences when compared to wildtype (WT) mice [41]. Interestingly, mice over-expressing α-
syn also display disruption in vesicular catecholaminergic neurotransmitter release, further 
supporting α-syn’s role in assisting in dopaminergic transmission [2, 41].  
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Alpha-Synuclein and Parkinson’s Disease 
PD is the most common of the synucleinopathies, and is the second most common 
neurodegenerative disease [11].  α-syn was first linked to PD when researchers found a family 
with autosomal-dominant Ala53Thr mutation in the SNCA gene region, the gene associated with 
α-syn transcription [23].  Since then, several other genes have been identified in association 
with PD, including: Parkin, PTEN-induced putative kinase 1 (PINK-1), protein deglicase (DJ-1), 
and leucine-rich repeat kinase 2 (LRRK2), and ATP13A2 [24-25].   
While the Ala53Thr was the first identified, and the most frequently observed mutation, 
several other SNCA mutations have since been linked to familial PD including Ala30Pro and 
Glu46Lys [23, 25]. These mutations are thought to cause PD by increasing α-syn likelihood to 
misfold and subsequently, aggregate [23, 26-27]. While polymorphisms influence inherited PD, 
duplications and triplications of the SNCA gene locus, are also associated with causing PD [23, 
27].  This process occurs simply by increasing α-syn synthesis above background basal levels. PD 
case’s from duplications and triplications of SNCA result in LB structure formation that are 
analogous to those found in SNCA mutations [1, 18-19, 23, 27]. This links WT α-syn as being 
capable of inducing PD pathology, an important finding, as the aggregation of WT α-syn helps to 
explain how idiopathic cases can occur which represent 85-90% of all PD diagnoses [23, 27].    
Oligomerization and Toxicity. 
As stated previously, α-syn found within LBs differs from the native unfolded monomer, 
as it is misfolded and oligomerized into higher order protein structures [244]. Included among 
these higher order structures are fibrils and oligomers which display different physiological 
qualities [244, 255]. The fibril species are resistant to proteinase K digestion, are detergent 
insoluble, and have an occluded N-terminal [244, 255]. It has been shown that sonication of 
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these of fibrillar species can induce α-syn accumulations within treated cells both in vitro and in 
vivo [32-34]. In contrast to fibrils, the lower order oligomerized structures can be degraded by 
proteinase K and are detergent soluble but are still capable of inducing in vitro aggregation of α-
syn and neurodegeneration within transgenic mouse models [3]. Therefore, it has led some to 
believe that these oligomers are the pre-existing structure to the fibrillar form [244, 255].   
Furthermore, some have argued that oligomers are specifically the pathological species 
responsible for α-syn’s ability to induce cellular damage and neurotoxicity [3-4, 31]. In vitro and 
in vivo studies have shown that dopamine and its metabolites are capable of inhibiting α-syn 
protofilament maturation, an intermediate between the oligomeric and fibrillar species [3, 29, 
31]. The implication being that the inhibition of protofilament maturation results in a specific, 
increased vulnerability within dopaminergic neurons due to prolonged oligomeric structure 
exposure [3, 29, 31]. However, in sufficient evidence exists to fully support the idea that 
oligomerized α-syn is responsible for its neurotoxic properties and some level of controversy 
remains. While the exact α-syn structure that induces pathogenesis remains unknown, it is 
generally agreed upon that the aggregation of α-syn is responsible for its neurotoxicity [7]. 
Evidence for Alpha-Synuclein Transmissbility among Cells -in vitro and in vivo. 
In addition to being able to induce neurotoxicity, α-syn has also been shown to be 
transferrable from cell-to-cell in both in vitro, as well as, in vivo, as observed in PD patients who 
have undergone embryonic nigral cell transplants [6, 33-36]. Post-mortem observation of these 
patients, showed LB-like pathological inclusions within their grafted neurons 14 years later [6]. 
The transfer of the Parkinson’s-like pathology within these stem-cells grafts in combination with 
α-syn’s ability cause protein inclusion within cells has led to the formation of hypothesis stating 
that α-syn is a prion-Like protein due to the similarities among the cellular spreading of prion 
disease [37, 38].  
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Prion-like proteins behave similar to prions within the same microenvironment, sharing 
the ability to cause cellular infectivity through similar mechanisms, they are both capable of 
amplification and transmissibility between cells, as well as causing dysregulation of the 
mechanisms that cells utilize to interfere with their degradation [33, 37, 40-41].  However, in 
contrast to true prions, prion-like proteins have not been demonstrated to be transmissible 
from person-to-person. 
Extracellular Vesicles 
Current evidence supports the idea that α-syn is secreted both within extracellular 
vesicles as well as in a naked, non-vesicular state.  In vitro work shows that when sonicated 
preformed fibrils of α-syn are added to cells they are readily taken up into cells and can result in 
progressing pathology [53]. However, how the pathology transfers from cells after this addition 
has not been identified.  It has been suggested that exosomes play a role in the transfers of α-
syn pathology, as pathological species of α-syn have been isolated from the cerebral spinal fluid 
(CSF) of patients with PD [54]. 
Additionally, It has been demonstrated that the isolation and subsequent addition of 
exosomes from cells over-expressing α-syn to wild-type (WT) cells, increased α-syn levels within 
the WT as well as caused increased α-syn aggregation.  Furthermore, within the same study, the 
isolated exosomes were shown to cause increased preferential transfer of oligomeric α-syn 
species in vitro when compared to non-vesicular oligomers, indicating that exosomes are able to 
transfer α-syn and its pathology to recipient cells and do so more effectively than non-vesicular 
α-syn [8]. Due to vesicular oligomeric α-syn’s ability to be preferentially taken up into cells it is 
possible that exosomes containing α-syn is a key component in the spread of synucleinopathy 
pathology among cells [8-9, 32-35].  
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Exosomes. 
Exosomes are small extracellular vesicles (EVs) with a diameter of 30 to 150nm [55-58]. 
Exosomes are the intraluminal vesicles (ILVs) that are released into the extracellular space upon 
the fusion of a specific type of late endosome called the multivesicular bodies (MVBs) with the 
plasma membrane [55-57]. Exosomes were originally thought to simply contain the unwanted 
waste of cells, however, further research has shown that exosomes are a part of normal 
physiological intercellular communication and transfer a variety of physiological relevant 
cargoes including RNA, proteins, and lipids [55, 60-65]. Additionally, these EVs are highly 
enriched in tetraspaninin proteins, a subfamily of proteins that organize membrane 
microdomains by forming clusters that interact with a large variety of cytosolic and 
transmembrane signaling proteins [55-56, 66]. Among these tetraspanins, CD9, CD63, CD81, 
CD82 and CD151 are broadly expressed among tissues and as a result are recognized as 
canonical markers of exosomes [55-56]. However, a variety of other proteins are also used as 
exosomal markers when such as Endosomal Sorting Complexes Required for Transport (ESCRT) 
proteins ALIX or TSG101. Additionally, the use of specific exosomal cargoes rather than 
canonical proteins can also be used to identify cell specific exosomes which may uniquely be 
secreted such as myelin from oligodendrocytes [67-68].  
Multivesicular Bodies. 
Endosomes can be classified into one of three categories: Early endosomes, late 
endosomes, and recycling endosomes [59]. Early endosomes containing cargoes that are fated 
for recycling make up the subpopulation of endosomes that develop into recycling endosomes 
while early endosomes that do not progress on to become secretory or degradative late 
endosomes [69-70]. Among these late endosomes are a specific group of MVBs which occur as a 
result of a large accumulation of ILVs, smaller vesicles that form within the late endosomes [59].   
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Before late endosomes begin to form ILVs, they go through a reorganization of their 
membrane which results in an enrichment of the tetraspanin proteins [66]. Afterward, the 
formation of ILVs is mediated by a series of proteins that form the ESCRT complexes [71].  ESCRT 
proteins are brought to the location where ILVs will be formed and begin to form their 
respective ESCRT complexes, of which four distinct ESCRT protein complexes (0, I, II, III) exist, 
each fulfilling a specific role in the formation of ILVs.  ESCRT 0 identifies ubiquitinated cargo [72]; 
ESCRT I and II are recruited by varying stimuli and are thought to participate in the initiation and 
formation process associated with the budding of the intraluminal membrane of the endosome; 
and that ESCRT III completes the ILV formation process by causing scission of the budding 
membrane [71-75].  
Exosomes and Synucleinopathies. 
Exosomes role in increased pathology is not exclusive to PD and as evidence suggests 
that exosomes participate in the spreading pathology of other major synucleinopathies [7-8, 10, 
54]. Exosomes containing higher levels of α-syn were found within the CSF of individuals with 
DLB [54].  Similar to PD, isolated exosomes from these individuals with DLB, were shown to be 
able to pass on pathological effects to H4, human neuroglioma cells, including increased levels 
of α-syn oligomerization which could be modulated in a dose dependent matter [54]. 
Genetic Mutations in Parkinson’s Disease alter Exosome Biogenesis. 
LRRK2. Several of the genetic mutations associated with familial PD have been shown to 
play roles associated with MVB formation [76-77]. Mutations within LRRK2 account for the 
largest amount of both familial cases and sporadic cases of PD [78-79].   And although LRRK2 
plays a role in several cellular processes, it is found to be important in the regulation of 
intracellular vesicle trafficking, as over-expression of LRRK2 results in decreased endocytic and 
exocytic vesicular release; indicating that LRRK2 plays a role in the either the release mechanism 
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or increases degradation of exosomes [77-81].  Furthermore, visualization of LRRK2 indicates 
that it associates with MVBs and that the pathological genetic mutation R1441C of LRRK2 leads 
to abnormally large MVBs and results in increased exosome release [81].      
VPS35. Other genetic mutations associated with PD have also been implicated as being 
part of the exosomal biogenesis pathway and MVB formation. Vacuolar protein sorting-
associated protein 35 (VPS35), a protein associated with the retromer complex [82]. The 
retromer complex is integral to proper endosomal cargo sorting where cargoes can then be 
trafficked back to the cell surface or sent back to the trans-golgi-network (TGN) via retrograde 
transport [82-84]. In addition to cell surface and TGN sorting, the retromer complex is important 
for the sorting of cargoes to special endosomal membrane compartments that are not degraded 
via lysosomes [83].  Furthermore, it has been shown that the retromer complex plays a role in 
autophagy and that it directly interacts with ATG8 (yeast), human paralogues microtubule-
associated protein 1 light chain 3 (LC3) and gamma-aminobutyric acid receptor-associated 
protein GABARAP, via VPS35 [85].  In addition, the PD familial mutation Asp620Asn of VPS35 
results in inhibited formation of the WASH complex and results in decreased transport of ATG9 
to autophagosomes, resulting in decreased autophagic activity [86].  
ATP 13A2. Furthermore, the P-type ATPase ion pump, ATP 13A2, the protein transcribed 
and translated from PD-related gene 9, plays a role in trafficking zinc into MVB [87]. Familial 
mutations of ATP 13A2 result in lysosomal dysfunction and increased α-syn accumulation as a 
result of altered trafficking of endosomal and autophagic cargoes [88-89].  In addition, the 
depletion of ATP 13A2 has been shown to induce zinc homeostasis dysregulated, as well as, 
both increase α-syn accumulation and cause mitochondria dysfunction [90-91]. While in 
contrast, upon ATP 13A2 over-expression, increased survivability and decreased α-syn 
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accumulation [91]. Additionally, the collected culture medium from cells over-expressing ATP 
13A2 resulted in increased levels of exosomal α-syn [91]. 
Unconventional Secretion  
While the transfer of α-syn from cell-to-cell represents one piece in understanding the 
transmission of synucleinopathy pathology, another is the underlying mechanisms associated 
with α-syn secretion. In the previously stated paragraphs, discussing PD mutations that are 
associated with the endosomal pathway and exosomal α-syn release, a common theme emerges 
regarding the autophagic/lysosomal degradative pathway.  Furthermore, the dysregulation of 
these processes is also associated with unconventional secretion of α-syn.  While 
unconventional secretion is technically any process that results in the secretion of cargo that 
does not occur through the conventional secretory pathway, increasing evidence suggests that 
orchestrated unconventional secretion of specific proteins occurs by utilizing autophagic 
mechanisms [92].  
In comparison to conventional protein secretion, very little is known about the exact 
mechanisms and pathways responsible for autophagic unconventional secretion. The bulk of 
information regarding how autophagy drives unconventional secretion was elucidated as a 
result of studies focusing on one of the earliest proteins identified to undergo secretion through 
this process, IL-1β [92, 94]. Similar to some conventional secretory proteins, IL-1β is synthesized 
as a pro-protein.  However, in contrast to conventional secretory proteins, IL-1β has no 
localization signal sequence, and is translated into the cytoplasm where it is readily found [94].  
Interestingly, upon activation of the specific inflammatory cascades that results in the formation 
of the inflammasome, IL-1β goes through proteolytic cleavage, from its inactive, pro-form to its 
active form, and is secreted within packaged membrane vesicles [94-97]. Until recently, the 
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mechanism for active IL-1β secretion was unknown; however, recent studies have indicated that 
active IL-1β secretion is regulated by autophagic machinery [96-97].  
In addition to IL-1β, IL-18 and HMGB1 are among the other proteins that have been 
identified to be secreted by autophagic machinery upon inflammasome activation [98]. Similar 
to IL-1β, both IL-18 and HMGB1 lack a signal sequence [98]. However, HMGB1 differentiates 
itself from IL-18 and IL-1β, as it is thought to go through indirect proteolytic cleavage upon 
inflammasome activation while IL-18 and IL-1β are thought to be directly cleaved by the 
inflammasome [98].  
Additionally both prion-like proteins α-syn and Aβ, one of the pathological proteins 
associated with another neurodegenerative disease, Alzheimer’s disease (AD), have also been 
indentified to undergo unconventional secretion as a result of autophagy [99]. However, in 
contrast to IL-1β, IL-18 and HMGB1, α-syn and Aβ secretion is not dependent on the activation 
of the inflammasome and while α-syn does not share all the previously stated traits of IL-1β, IL-
18, or HMGB1, it is directly translated into the cytoplasm and does not appear to have a specific 
localization sequence [9, 94-99].  Therefore, it is thought that these characteristics may be 
shared among the proteins that undergo autophagic regulated unconventional secretion.  
Autophagy  
Evidence suggests that the degradation of α-syn occurs via both chaperone-mediate 
autophagy (CMA) and macroautophagy, as well as, by the ubiquitin proteasomal system (UPS) 
which will be talked about in later sections [104-107]. CMA is a form of autophagy where 
specific cargoes are directly taken to the lysosome rather than being engulfed within an 
autophagosome which occurs in macroautophagy. In CMA cargoes are recognized by their 
exposed KFERQ amino acid motif by heat shock protein 70 kDa protein 8 (HSC70/HSP8A) [100-
101]. Bound cargo is then taken to lysosome where HSC70 binds lysosomal associated 
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membrane protein 2 A (LAMP2A) and then is unfolded [100-101]. After the specific cargo is 
unfolded it is then translocated into the lysosome for degradation [100]. However, it has been 
hypothesized that macroautophagy (referred hereafter as autophagy) is the major pathway 
associated with the removal of α-syn oligomers [104-107]. As elucidated in previous sections, 
the role of autophagy has recently expanded beyond the scope of degradation and has also 
been shown to be a part of the pathways associated with the unconventional secretion of 
specific proteins. Among these proteins includes the aggregate forming protein α-syn. 
Evidence suggests that α-syn is recruited to both degradative, the process associated 
with autophagosome and lysosome fusion and breakdown of cargoes, and the secretory, the 
process associated with the autophagosome and plasma membrane fusion, autophagic 
pathways [107]. Our lab and others have shown that α-syn aggregates are recruited to acidified 
autophagic compartments associated with autophagic degradation [108-111].  As of now, only a 
few differences have been indentified between degradative and secretory autophagosomes. 
Additionally, it has been proposed that both degradative and secretory autophagosomes start 
from a similar origin point and become differentiated at a specific unknown branch point [112].  
Therefore, having an understanding of how the precursory structure that develops through 
expansion into the autophagosome, the autophagophore is important for understanding both 
degradative and secretory autophagy. This process is also highlighted in figure 1 of the 
appendix.  
Autophagosome initiation.  
ULK complex. Classically autophagic initiation requires the ULK Complex and Beclin-1 
complex.  The ULK complex gets its name as result of the two proteins found within it, UNC51 
like Ser/Thr kinase 1 (ULK1) and UNC51 like Ser/Thr kinase 2 (ULK2) [112-113].  Additionally, the 
ULK complex is made up of two other proteins ATG101 and the 200 kDa FAK family kinase 
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interacting protein (FIP200) [112-113].  During activation, such as starvation, ULK1 and ULK2 
phosphorylate a variety of proteins including FIP200 and ATG13 resulting in the formation of the 
complex [112-113].  Additionally, both ULK1 and ULK2 have a carboxy-terminal domain (CTD) 
that allows them to associate with membranes which is thought to be important to the 
formation of the autophagosome [112-113]. Also, the ULK complex is predominantly negatively 
regulated by mTOR1 which is directly bound to ULK1 and ULK2 thus inactivating them [114-115]. 
In contrast, the ULK complex can is positively regulated by AMP-activated protein kinase (AMPK) 
[114-115].  
Beclin-1 complex and PI3K. The Beclin-1 complex is important to autophagic initiation 
because of its ability to induce the formation of the autophagy specific class III PI3K [116-118]. 
The Beclin-1 complex is composed of Beclin-1, vacuolar protein sorting 34 (VPS34/ PI3KC3), 
Vacuolar sorting protein 15 (VPS15/p150), Bif-1, Rubicon, and ATG14 [116-121]. Beclin-1, VPS34, 
VPS15, and either ATG14 or ultraviolet irradiation resistance-associated gene (UVRAG) is 
necessary for its activation [117-121]. The titular Activating Molecule of Beclin-1 Related 
Autophagy 1 (AMBRA1) is a scaffolding protein, which interacts with Beclin-1 among other 
proteins and helps in assembling the proteins necessary to form the active complex [116-121]. 
Furthermore, AMBRA1 is positively regulated by ULK1 and is negatively by B cell lymphoma 2 
(Bcl-2) and Rubicon [119-120]. Upon activation of the Beclin-1 complex VPS15 heterodimerizes 
with VPS34, regulating its activity [121]. This heterodimerization allows for VPS34 to catalyze the 
phosphorylation of phosphoinositides, an integral part of autophagophore initiation process 
[121].  
ATG protein complexes. Two autophagy-related protein (ATG) systems are utilized as 
part of the autophagic process. These systems result in the formation of two distinct ATG 
complexes which are important in the elongation of the autophagophore into the 
17 
 
 
autophagosome. Additionally, these two ATG systems both rely on the E1 ubiquitin-like (UBL) 
protein, ATG7 [103]. However, after utilizing ATG7 they are brought to two distinct E2 UBL ATG 
proteins.  
ATG12-ATG5-ATG16 complex. In the formation of the first complex, ATG7 binds to 
ATG12 where it brings it into close proximity with the ATG 10, the E2 UBL. ATG10 binds to 
ATG12 where it assistants in binding ATG12 to ATG5 resulting in beginnings of final complex, 
denoted as ATG12-ATG5 [103, 122-123]. The bound ATG12-ATG5 assembles with ATG16 to form 
the ATG12-ATG5-ATG16 complex [103, 123-126]. ATG16 acts as an E3 UBL protein where it 
brings the full ATG12-ATG5-ATG16 complex onto the expanding autophagophore [103, 123-
126].  
ATG-LC3 complex. During this process the second ATG complex also forms. The second 
of the two complexes is important in the translocation and processing of LC3 [103, 127-128]. 
Similar to the first ATG system, the second system also utilizes the E1 UBL protein ATG7 [103].  
However, the process begins with the processing of LC3 from its precursor pro-form by ATG4, a 
cysteine protease [103, 122].  The cleavage of pro-LC3 into LC3, denoted as LC3-I allows for 
ATG7, the E1 UBL protein to recognize and bind to it. The binding of LC3-I to ATG7 allows for an 
E1-E2 like reaction resulting in the binding with ATG3 the E2 UBL protein [103, 122, 127-128]. 
The LC3-I bound to ATG3 goes through the lipidation process where the now exposed glycine on 
the LC3-I becomes conjugated with the phospholipid, phosphotidylethanolamine (PE) [103, 
129]. This process is mediated by the first ATG assembly complex, ATG12-ATG5-ATG16, which 
acts as the E3 UBL protein [103, 129-131]. The PE conjugation creates the lipid anchor that 
allows for LC3-I’s association with the autophagophore [103, 130-131]. Subsequently, this 
changes LC3-I’s nomenclature from LC3-I to LC3-II indicating PE is bound to LC3 [103]. This 
process is necessary for the autophagophore to continue elongation into an autophagosome 
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[103, 124].  Additionally, this complex is also responsible for the recruitment of GABARAP to the 
autophagosome [83]. GABARAP plays a role in the trafficking of the autophagosome and the 
recruitment of specific cargoes to the autophagophore [83].  
Elongation and degradation. During the elongation process cytoplasmic contents, such 
as aggregated α-syn, are engulfed by autophagophore, an isolated portion of double membrane 
and are fully sequestered when the autophagophore encloses to form the autophagosome [103, 
128-129, 132]. The autophagosome then undergoes mediated fusion with the lysosome, 
resulting in the formation of the autophagolysosome. This process exposes the cytoplasmic 
contents enclosed within the autophagosome to the hydrolytic enzymes within the lysosome 
thus resulting in their degradation [9, 132]. 
Autophagosome formation and Omegasomes. 
While its exact source remains unidentified, the isolated portion of double membrane 
that becomes the autophagophore is thought to originate primarily from the endoplasmic 
reticulum (ER) but may also be from another organelle such as the golgi apparatus, 
mitochondria, or possibly the plasma membrane, [9, 132-135].  In support of the ER being the 
primary source of membrane, during starvation, a specific portion of the ER, characterized as 
the omegasome due to its shape, has been shown to become isolated [121, 136, 137].  These 
isolated membranes are shown to be enriched with ATG14, and the phospholipid, 
phosphatidylinositol 3-phosphate (PI3P) which results in the binding of the autophagic effectors, 
WD-repeat domain phosphoinositide-interacting protein (WIPI2) and double FYVE-containing 
protein (DFCP1) [102, 121, 137]. While the exact reason for why PI3P enrichment is important 
for autophagic function has yet to be identified, it is essential for autophagophore’s expansion 
into the autophagosome [138-139]. 
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Starvation induced versus quality control Autophagy. 
Degradative autophagy has a variety of functions including: 1) The recycling of nutrients 
within the cell during times of starvation; 2) cellular homeostatic functions, including the 
regulated breakdown of damaged organelles, the removal of pathological invades such as 
bacteria and viruses and the elimination of aggregated and aggregate prone proteins such as 
misfolded α-syn [102-103, 140-141]. However, while degradative autophagy is essential to 
cellular processes, the activation of autophagy can generally attributed to two different 
justifications: non-discriminate degradation as a result of starvation and quality control where 
specific cargoes are targeted for elimination [141-142].  In starvation induced autophagy, 
autophagophores indiscriminately engulf portions of cytoplasm with the primary goal of 
recycling of nutrients due to the lack availability [141-142].  
In contrast, in quality control based autophagy, the autophagic cargo is selectively 
targeted for degradation by poly-ubiquitinated post translation modifications [140-147]. These 
cargoes include (but are not limited to) aggregated proteins, damaged organelles and long lived 
proteins [140-147]. Selectivity of the quality control based autophagy is driven by specific 
ubiquitin adaptor binding proteins such as p62/SQSTM1, NBR1, NDP52, Optineurin, and HDAC6 
[143-149]. These adaptor proteins are able to directly link their ubiquitinated targets directly to 
LC3B, thus resulting in targeted degradation.  It is believed that aggregated proteins, such as α-
syn, are primarily targeted for autophagy via this mechanism [9, 150].  
Activation mechanisms of autophagy . 
The specificity of whether starvation induced or quality control autophagy occurs is 
thought to be differentiated through the mechanisms associated with autophagy activation. 
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These pathways have been elucidated via specific small molecule activators of autophagy, 
among which is rapamycin [151]. 
Rapamycin. Rapamycin is naturally produced substrate from the bacteria Streptomyces 
hygroscopicus and is of a macrolide composition known to have immunosuppressant effects 
[152].  Rapamycin is membrane-permeable and, upon treatment, rapamycin binds to 12-kDa 
FK506-binding protein (FKB12) forming a complex while simultaneously causing its inhibition 
[151, 153]. This rapamycin-FKB12 complex binds directly and inhibits mTOR1 [153-155].  
mTOR1. mTOR1 functions to inhibit autophagy via phosphorylation of both ATG13 and 
ULK1 (specifically at serine 758) resulting in the inhibition of the ULK complex; one of the 
primary initiating complexes of autophagy [115, 155]. When mTOR1 is inhibited, ULK1/2 activity 
increases thus resulting in phosphorylation of the two important ULK complex subunits, ATG13 
and FIP2000 [113, 156-157]. This process is thought to increase starvation induced autophagy 
rather than quality control based autophagy [102, 112]. 
mTOR2. While mTOR1 is thought to be important in cell cycle progression as a result of 
nutrient availability, it is thought that mTOR2 is influences the regulation of cell proliferation 
and cell survivability. Additionally, prolonged rapamycin and/or high dose treatment has shown 
to also result in mTOR2 inhibition [158-160]. However, due to mTOR2’s relatively recent 
identification, all the possible functions that mTOR2 influences have still yet to be elucidated.  
Trehalose.  Another small molecule associated with the activation of autophagy is 
trehalose. Although the mechanism associated with trehalose’s ability to cause an upregulation 
of autophagy has not been identified, it has an interesting role in neurodegenerative diseases 
due to its ability to increase clearance of aggregate forming proteins, including α-syn [165-166]. 
Trehalose is a non-reducing disaccharide that occurs when two glucose units are joined by 1,1 
alpha bond [167]. Although both rapamycin and trehalose increase autophagic activity, In 
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contrast to rapamycin, trehalose has been shown to increase in autophagic activity through an 
mTOR independent pathway and appears to effect autophagosome production differently [9, 
168]. Interestingly, trehalose has also been shown to activate TFEB, a transcription factor that 
increases lysosome biogenesis [169]. While another paper has shown that TFEB causes an 
increase in LC3-II positive vesicles, indicating that TFEB increases autophagy [170]. Studies 
conducted by DeBosch et al., within hepatocytes have proposed that trehalose’s mechanism of 
action for increasing autophagy occurs due trehalose’s ability to cause inhibition of glucose 
transports (GLUT1, GLUT2, GLUT3, GLUT4, and GLUT8) resulting in activation of AMPK which 
phosphorylates ULK1 [168].   
In addition to trehalose’s ability to activate autophagy, trehalose has also been 
suggested to play a role in directly affecting protein aggregate folding. A modeling study 
conducted by Allison et al., 1999, proposed a mechanism on how trehalose may stabilize protein 
folding through the use of hydrogen bonds [171].  Additionally, trehalose has thought to alter 
protein folding of aggregate proteins or potentially change the thermodynamics of aggregate 
forming proteins resulting in change of aggregate forming proteins back to their native 
conformation [172].   
Secretory Autophagy. 
In contrast to degradative autophagy, the mechanisms regarding secretory autophagy 
are not as well studied, due to its relatively new discovery. The majority of studies that have 
identified the mechanisms associated with secretory autophagy were conducted within yeast; 
and then their protein homologues/paralogues were identified within mammalian cells.  
Currently, two specific proteins have been identified to be important in the 
unconventional secretion of both IL-1β and α-syn:  The first, GRASP55 protein found in yeast, 
mammalian homologue ATG5, affects autophagy in general [124, 173]. The second is RAB8a, a 
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GTPase, which has been identified to be necessary for secretory autophagy as a result of its 
function in the sorting of cargo to the plasma membrane [9]. Interestingly, a closely related 
GTPase, RAB8b has been suggested to be important in the degradative autophagy [174]. 
Potentially illustrating, a branch point in which autophagosomes may share a common origin 
before being distinguished for degradation or secretion.  Furthermore, it has been 
demonstrated that yeast secretory autophagy requires the specific snare protein Sso1 which is 
integral for autophagosomes to associate with the plasma membrane [175]. In contrast, 
degradative autophagy requires the VAM7/VAM3 snare proteins for vacuoles to fuse with 
lysosomes [175]. These differences found within yeast autophagosomes provides further 
evidence suggesting that a similar precursory origin may exist before autophagosomes are 
distinguished as being degradative and secretory in nature. 
Compartments of unconventional protein secretion. Research on yeast has identified 
compartments of unconventional protein secretion (CUPS), which resemble the mammalian 
omegasome, a precursory formation to the autophagophore located on the membrane of the 
ER [137, 176]. During starvation, GRASP re-localizes to CUPS within yeast which serves as a 
marker signifying the formation as secretory [176]. A true secretory marker homologue, such as 
GRASP, has yet to be identified within mammalian cells. Additionally, because omegasomes do 
not appear to form within yeast cells, and because mammalian cells have not been identified to 
form CUPS, whether these seemingly similar formations are actually distinct still needs to be 
elucidated. However, if a true GRASP homologue was identified within mammalian cells, this 
may begin to shed light on the possible connection between CUPS and omegasomes.  
Additionally, the identification of the mammalian GRASP would serve as evidence supporting 
the idea that degradative and secretory autophagosomes share an initial precursory origin of 
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ATG proteins and that the distinction between degradation and secretion occurs later in the 
autophagosome maturation pathway.    
Autophagosome formation is important to the secretion of alpha-synuclein. 
Autophagosome inhibition results in decreased alpha-synuclein secretion. Currently, the two 
processes thought to be important in increasing autophagic dependent secretion of α-syn are: 
The upregulation of autophagy, specifically increasing the formation of the autophagosomes [9, 
173]; and altering the properties associated with autophagic degradation, generally due to 
inhibition of autophagosome and acidified lysosome fusion [9].  However, autophagosome and 
acidified lysosome fusion is also the result of correct microtubule trafficking. 
3-MA. In support of the idea that α-syn secretion is dependent on autophagosome 
formation, the study conducted by Ejlerskov P et al., 2013, found that the treatment of 3-
methyladenine (3-MA), a known inhibitor of the autophagy specific, class III PI3K 
(VPS34/PI3KC3), in cells over-expressing both the genetic mutant of α-syn A30P, as well as, p25α 
had significantly decreased levels of α-syn secretion compared to untreated controls [9]. 
Interestingly, 3-MA treatment is also linked to α-syn accumulation. Furthermore, siRNA 
mediated knock-down of ATG5, a protein important in the elongation of the autophagophore, 
resulted in significantly decreased α-syn secretion [9]. These results suggest that the 
autophagosome formation and elongation play a role in autophagy dependent secretion of α-
syn [9].  
Promotion of Autophagophore formation increases alpha-synuclein secretion. 
Contrastingly, promotion of autophagosome formation increased α-syn secretion. The over-
expression of both α-syn A30P and Rab1A, a protein implicated in autophagophore promotion, 
significantly increased α-syn secretion [9, 176].  
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Increases in autophagy increase alpha-synuclein secretion. While in contrast, when the 
cells over-expressing the α-syn A30P also over-expressed p25α showed significant increases in 
α-syn secretion when they were treated with the autophagy initiating small molecule, trehalose 
[9].  In addition to trehalose treatment, rapamycin, another autophagy activating drug, in cells 
over-expressing the mutant form of α-syn (A30P) saw considerable fold increases in α-syn 
secretion and modest but significant levels, respectively [9].  This was thought to occur due to 
differences in the mechanisms associated with autophagic activation, as described previously 
[9].  
Autophagosome trafficking direction. HDAC6. As stated previously, a specific subset of 
autophagy proteins help in the degradation of specific targets as a function of quality control 
autophagy. These specific adaptor proteins, such as P62/SQSTM1, and HDAC6 contain binding 
motifs associated with the recognition of both distinct poly-ubiquitin post-translational 
modifications, as well as, LC3B [144-145, 148-150]. These binding motifs allow for the specific 
translocation of ubiquitinated targets to center of the autophagophore [144-145, 148-150]. 
Among these adaptor proteins, HDAC6 also displays another function; it is also capable of linking 
its targets to dynein-dynactin motor proteins [148]. Within neurons P62/SQSTM1 and HDAC6 
are necessary for the formation of inclusion bodies as result of their ability to direct the 
transportation of ubiquitinated cargo retrograde, toward the minus end of the microtubule 
pathway, and toward the nucleus [177]. Additionally, knocking-down HDAC6 has been shown to 
increase α-syn secretion [9]. 
P25α. Building off of HDAC6’s ability to affect retrograde transport of marked 
ubiquitinated cargo, several studies has been published focusing on the Tubulin Polymerization-
promoting protein (P25α/TPPP), which runs conversely to HDAC6. While HDAC6 increases 
retrograde microtubule transport, P25α increases anterograde transport by binding to the plus 
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end of microtubule assemblies, decreasing their plus end growth rate and reducing 
depolymerization [178]. However, it was not until a study found that P25α also inhibits HDAC6’s 
deacetylase activity that another paper followed up on whether p25α was capable of influencing 
α-syn secretion [179]. The study found that the over expression, of p25α increased α-syn 
secretion, and that the same effect could be achieved by knocking down HDAC6 or treating with 
the HDAC6 inhibitor, trichostatin, and these processes were linked to increased secretion of α-
syn [9].  Additionally, p25α potentially increases α-syn aggregation and is found within lewy 
bodies [179]. P25α is generally found with oligodendroglial cells however, dopaminergic 
neurons synthesize p25α in abnormal levels during PD progression [178]. 
Autophagy and Exosomes 
Amphisomes.  
As previous stated, the secretion of exosomal α-syn is thought to be one of mechanisms 
associated with the transfer of pathological α-syn among cells. Additionally, several of the 
genetic mutations associated with familial PD are associated exosome secretion but linked to 
dysregulation of autophagic pathways. While secretory autophagic mechanisms have been 
shown to influence α-syn secretion, areas of overlap between exosome biogenesis and 
autophagy exist. Therefore, it should come as no surprise that the exosomal secretion of α-syn is 
also influenced by autophagy. Specifically, one of the direct ways that exosomes and autophagy 
interrelate is through the production of the amphisomes.  
Amphisomes are a hybridized organelle that results from the fusion of autophagosomes 
and endosomes which include MVBs.  Amphisomes can then continue down the autophagic 
pathway where they can go through fusion with the lysosome resulting in degradation or bind 
with the plasma membrane and combined cargoes are released into the extracellular space 
[180-181].   
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Amphisome formation. The fusion of autophagosomes with endosomes to form 
amphisomes, as well as, the fusion of amphisomes with lysosome is a rab7 dependent process 
[182]. Similarly, these fusions are also dependent on VAMP8 for the priming of the SNARE 
protein complex that forms by the autophagosomal Syntaxin 17 and the lysosomal/endosomal 
SNAP29 [183, 186].  Interestingly, specific fusion of autophagosomes and late endosomes for 
the creation of amphisomes is also dependent on autophagosome phosphatidylinositol 4-
phosphate (PI4P) that forms as a result of GABARAP’s recruitment of phosphatidylinositol 4-
phosphate kinase II (PI4KII) [185]. The depletion of either PI4KII or its substrate PI4P prevents 
the fusion of autophagosomes and late endosomes. Conversely, while the fusion of 
autophagosomes with lysosomes utilizes both rab7 and the Syntaxin17-SNAP29 complex, its 
fusion is mediated by autophagic protein homolog (EPG5) rather than PI4P [186]. 
Theoretically, amphisomes seemingly provide the ideal environment for α-syn 
aggregation, as it has been shown that α-syn aggregation increases in mildly acid conditions due 
to increased fragmenting and secondary nucleation of oligomerized species that are found 
within amphisomes [187]. Additionally, amphisomes are particularly enriched in the 
glycosphingolipids GM1 and GM3 that are often found within exosomes but also shown to 
increase α-syn aggregation within MVBs [188]. While more information is needed before any 
one conclusion can be made, the formation of amphisomes may explain how autophagic drugs 
influence the secretion of exosomal α-syn.  
Bafilomycin-A1. 
Various drugs have been shown to influence autophagy and autophagic based secretion 
of α-syn, several of the most prominent have already been covered earlier within previous 
sections, however, bafilomycin-A1, the lysosomal inhibitor, provides an interesting point of 
intersection between autophagy, the endolysosomal pathway, and exosomes.   
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Bafilomycin-A1 is a naturally forming macrolide substrate that inhibits the acidification 
of lysosomes by blocking the vacuolar H+-ATPase [189].  Additionally, bafilomycin-A1 also 
prevents the fusion of autophagosomes and lysosomes [189-190]. A recent study in which 
drosophila were genetically depleted of the vacuolar H+-ATPase found that impotent lysosomes 
still fused with autophagosomes [190]. In addition, when cells were depleted of the 
autolysosomal SNARE protein, Syntaxin17, the fusion of autophagosomes and lysosomes were 
prevented despite the proper acidification of lysosomes; indicating that the vacuolar H+-ATPase 
was not responsible for this affect. The study identified that bafilomycin-A1’s also inhibits the ER 
Ca2+-ATPase, ATP2A/SERCA, which is important in maintaining proper calcium balance within the 
cytosol [190].  This inhibition of SERCA by bafilomycin-A1 and the subsequent calcium 
dysregulation is thought to prevent the fusion of autophagosomes and lysosomes due to 
Syntaxin17 mediated fusion dependency on calcium [190]. Supporting this idea, the treatment 
of thapsigargin, a specific inhibitor of SERCA, also prevents the fusion of autophagosomes and 
lysosomes [191].  
Several studies have shown that cells over-expressing α-syn treated with bafilomycin-A1 
not only caused increased levels of raw α-syn secretion but also caused a significant increase 
within the exosomal population [8, 49, 88]. Interestingly, the relative fold difference in the 
exosomal α-syn release among the bafilomycin-A1 and DMSO control condition was higher than 
the fold difference in general α-syn release for the same treatment paradigm [8]. One of the 
studies offered the explanation for the bafilomycin-A1 induced increase in exosomal α-syn 
secretion occurred due to elevated levels of MVB and autophagosome fusion and because of 
the lysosomal inhibition, the cell removes the α-syn via secretion [8].  Consistent with this idea, 
the increased activation of autophagy has been shown to also increase the interaction between 
MVBs and autophagosomes [192]. 
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Proteasomal Inhibitors Influence Alpha-Synuclein Secretion 
Introduction to the Proteasome. 
In addition to the autophagy/endolysosomal pathway, the other primary degradative 
system within the cell is the proteasomal degradation pathway. The proteasomal degradative 
pathway is dynamic and changes depending on the needs of the cell and is reflected in the 
specificity of various types of proteosomes. These specificities are done on a genetic level by 
specific pathways and responses that alter the transcription of different subunits of the 
proteasome, thereby imparting changes on what proteasomes recognize or degrade [194-196]. 
Also, post-translational modification of the proteasome influences its degradative capacity and 
the cell can also influence proteasomal degrative systems by changing the levels of degradation 
of the proteasomes themselves [195]. Finally, proteasomal capacity is also influenced by other 
factors such as oxidative stress, aberrant or misfolded proteins, chemicals or drugs, as well as, 
age all of which in altering the influence of cellular levels and oxidiative modifications of the 
proteasomes [196-197]. In particular, the 26S proteasome plays an important role in the 
removal of aggregate and misfolded proteins such as α-syn by utilizing the ubiquitin proteasome 
system (UPS) [41]. In addition to the previous stated factors, the processes that negatively 
influence proteasome activity are particularly important within the context synucleinopathies 
[197-199].  As impaired proteasomal function is associated with the accumulation of misfolded 
proteins such as α-syn [198-199].  
Defining the 26S Proteasome. 
The proteasome is made up two primary protein complexes, the 20S core particle and 
the 19S regulatory particle [103].  The 20S core is composed of a stack of four heptameric rings 
[103]. Each ring represents one of the two subunits of the 20S core particle known as the either 
the alpha or beta subunit [103].  The beta heptameric ring subunits (β1-7) are found in the 
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interior of the stacked four rings. The β1, β2, and β5 of the β subunit are catalytic, each with 
unique specificity for substrates due to their chymotrypsin-like, trypsin-like, and caspase-like 
properties [103].  While in contrast to the beta subunits, the alpha heptameric ring subunits sit 
on the exterior of the 20S core particle and are largely structural in nature [103].  
The 19S regulatory particle recognizes ubiquitinated proteins and is important in 
preparing proteins for degradation by the 20S core particle. The 19S regulatory particle uses ATP 
hydrolysis to unfold proteins and translocates them through its narrow pore where they are 
degraded by the core particle [200].  The central machinery of the 19S regulatory particle is 
composed of a hexameric ring with six AAA ATPases abbreviated as RPT1-6 [200].  Additionally, 
the 19S regulatory particle is connected to the alpha-ring of the 20S core particle via the C-
terminals of its six AAA ATPases and is able to open the gated entry channel where it is 
connected to the core particle [201].   
Proteasome Response Pathway. 
NRF1. The transcription factors nuclear factor like 1 and 2 (NRF1 & NRF2, respectively), 
are important in the upregulation of proteasomes [202]. NRF1 is found bound to the ER where 
upon activation translocates into the nucleus and binds to its response element, antioxidant 
response element (ARE) [202-204]. Under normal conditions, NRF1 translocates from the ER to 
the cytosol via the ATPase, p97, where it is then ubiquitinated and degraded [202]. Activation of 
NRF1 causes an increase in proteasomal transcription and occurs when the proteasomal 
capacity needs to be increased or when inhibition of proteasomal acitivity has occurred [202, 
205-206]. 
NRF2. Contrastingly, NRF2 is found readily within the cytosol and becomes activated in 
response to oxidative stress [207]. NRF2 under normal conditions is not active, held in its 
inactive form by Kelch like-ECH-associated protein (KEAP1), and is readily ubiquitinated by Cullin 
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3 and degraded [208-210]. However, oxidative stress disrupts this interaction and leads to NRF2 
accumulation. The accumulated NRF2 dimerizes, translocates within the nucleus and binds to 
ARE [209]. 
Additionally, NRF2 also associates with the mitochondrial membrane during proteasome 
inhibition due its association with PGAM5 [207]. Upon increased mitochondrial generated 
reactive oxygen species (ROS), indicating mitochondria damage/failure, activation of NRF2 
occurs [210].  The resulting ROS from the mitochondria causes disassociation of NRF2 from the 
membrane and activation [209-201]. Activation of NRF2 via this mitochondrial pathway also 
results in increased transcription of heat shock proteins as well as proteasomal subunits [211].  
It has been reported that increased age seems to decrease this NRF2 mitochondrial associated 
pathway, and as a result, less proteasomal clearance occurs along with reduced levels of heat-
shock proteins transciption [207].  Due to age being the highest correlating risk factor with 
idiopathic PD [11], it has been implicated that this process may contribute to PD symptom 
exacerbation [207].  
Crosstalk between the Proteasome and Autophagy. 
In addition, to the previously talked about activation pathway of NRF1, it has been 
shown that mTOR1, through post-translational activation of SREBP1, is also able to positively 
affecting NRF1 activation [212]. As stated previously, mTOR1 is also important in the regulation 
of autophagy, and also important in the regulation of the proteasomal degradation, indicating 
that crosstalk among the two systems exists. In fact, a wide variety of evidence suggests that 
crosstalk between the proteasomal and autophagic pathway occurs and during increased 
proteasomal inhibition, quality control based autophagy will begin to compensate for the loss in 
activity [213-218].  
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Several studies have implied that both AMPK and mTOR1 have indirect mechanisms of 
recognizing when reduced proteasomal activity is occurring [213-214]. Additionally, it has been 
shown that when inhibition of the 26S proteasome occurred, an increase in AMPK and 
autophagic activity was observed within a variety of cell-lines [214-216].  Furthermore, within 
hippocampal neurons, the dysregulation of the 26S proteasome results in decreased activity of 
glycogen synthase kinase-3β (GSK-3β) [215]. This decreased activity in turn leads to an increase 
in the activation of AMPK thus resulting in upregulating autophagic activity [215]. Interestingly, 
this pathway within these hippocampal neurons also seems to decline with age [215].   
Another example of the crosstalk between proteasome and autophagic degradative 
pathways is the proteasomal degradation of ULK1 which moderates the activation of autophagy 
as part of the ULK complex [217]. Further examples include two specific processes that are 
mediated by p62. p62 mediates the autophagic degradation of KEAP1, the protein response for 
the inactivation of NRF2 [218].  Additionally, it has been shown that degradation of LC3, which 
normally occurs via proteolysis, can be inhibited by the binding of p62 to LC3 resulting indirectly 
in contributing to increased autophagic activity [218]. Further evidence for crosstalk, has been 
demonstrated by proteasomal inhibition via small molecules such as MG 132 which have been 
demonstrated to increase autophagic activity [220-221]. Interestingly, MG 132 treatment is also 
linked to the secretion of α-syn [9].   
MG 132. Carbobenzoxy-Leu-Leu-leucinal or MG 132 is an aldehyde peptide that causes 
inhibition of chymotrypsin-like activity and therefore, results in blockage of the proteolytic 
activity of the 26S proteasome [219]. While MG 132 directly inhibits the proteasome it also 
linked to increases in autophagic activity [221]. Lan et al., 2004, found that when PC-12 cells 
expressing A53T α-syn were treated with MG 132 and lysotracker, a proprietary fluorescent dye 
that accumulates within acidic compartments, an increase in lysotracker distinct positive puncta 
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occurred [221]. Additionally, the treatment of MG 132 was shown to result in an increase level 
LC3-II within the same PC-12 cells [221].  Furthermore, it has been reported that MG 132 
treatment also results in an increase in α-syn accumulation [220-221]. These results indicate 
that MG 132 treatment leads to an increase of autophagosome formation, likely as a 
consequence of MG 132 inhibition of UPS, while also implicating the UPS in removal of α-syn 
based on its accumulation. 
In addition to MG 132’s ability to increase α-syn accumulation, the treatment of MG 132 
has been shown to increase α-syn secretion [222].  A study looking at α-syn secretion as result of 
chemical stressors found that MG 132 increased α-syn secretion by seven fold over control 
[222].  Additionally, the exosomal fraction of cultured medium from the MG 132 cells indicated 
that a 2-fold increase in vesicular α-syn occurred [222]. Although the mechanism for how α-syn 
secretion is occurring has not been identified, it is possible that the inhibition of the 26S 
proteasome by MG 132 is causing an increase in autophagic based secretion of α-syn. However, 
more information is necessary before one can make this conclusion. 
While studies conducted on proteasome inhibition due MG 132 treatment link 
proteasome function to autophagy, as well as, α-syn accumulation and secretion.  Mitochondrial 
degradation and turnover is another pathway directly showing a link between the proteasome 
and autophagy. MG 132 treatment has been shown to increase ROS levels within the cell and 
the depletion of GSH, indicative of mitochondrial dysfunction [219].  Furthermore, genetic 
mutations directly associated with mitochondrial turnover, such as PINK1 and Parkin, also tie 
cooperative degradation of the proteasome and autophagy to PD pathology [222-223]. 
Proteasome’s role in Mitochondrial Regulation and Degradation. 
The regulation of mitochondria integrity is an example in which both the UPS and 
autophagic pathway play an orchestrated role in maintaining mitochondrial balance and 
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subsequently the management of mitochondrial related ROS. However, mitochondria 
dysfunction and subsequent ROS generation has been shown to play a role in a variety of 
neurodegenerative diseases including synucleinopathies [223]. Dysregulation of either of the 
autophagic or UPS degradative pathways is associated with decreased clearance of 
mitochondria resulting in further damaging ROS exposure and exacerbate general cellular 
dysfunction [223].  
Mitochondria are essential organelles within mammalian cells and they participate in a 
variety of functions including high efficiency energy production via oxidation [224].  Under 
normal conditions, the mitochondria, and its subsequent systems associated with maintaining 
oxidative stress, are equipped to deal with this oxidation [224]. However, upon damage or 
dysregulation of the mitochondria, the management of oxidation becomes unregulated 
resulting in the mitochondria becoming a large source of ROS for the cell [225-227]. Depending 
on the level of dysfunction or damage, mitochondria can provoke a few different interconnected 
responses. Among these responses are the adaptive stress response and mitophagy [224-227].  
The first-line of response upon mitochondrial dysfunction is the recruitment of the 26S 
proteasome, tasked with the responsibility of degrading the damaged outer membrane proteins 
of the mitochondria [229]. If the removal of the damaged outer membrane does not rescue the 
mitochondrial function, the mitochondria will be targeted for degradation via mitophagy, a 
specialized form of quality control based autophagy [229]. Mitophagy is occurs via one of two 
pathways, the receptor mediated pathway or the ubiquitin dependent pathway [230-231].  Of 
these two pathways, the ubiquitin dependent pathway is particularly relevant to PD pathology 
as it is regulated by both PINK1 and Parkin, in which mutations in both PINK1 and Parkin are 
associated with familial PD [231]. This ubiquitin dependent pathway occurs upon depolarization 
of the mitochondrial membrane resulting in PINK1 activation [231-232]. PINK1 then functions to 
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recruit the E3 ubiquitin ligase Parkin [231-232]. Parkin activation results in increased poly-
ubiquitination of multiple outer-membrane mitochondrial proteins [231-232].  The poly-
ubiquitination allows for the recruitment of the ubiquitin mediators of quality control based 
autophagy such as NDP52, OPTN, p62/SQSTM1, and NBR1 [232].  Additionally, it has been 
shown that mitophagy is also dependent on the proteasome, as Parkin been shown to also 
associate with the UPS via the ubiquitin receptor, Rpn-13.  Furthermore, the deletion of Rpn-13 
was shown to slowdown the turnover of mitochondrial clearance time [233].  
Rotenone.  In addition to genetic mutations in PINK1 and Parkin being linked to PD and 
mitochondrial dysfunction, the pesticide rotenone which causes mitochondrial dysregulation, 
has been shown to cause PD pathology. Rotenone was first linked to PD after a paper published 
results showing increased α-syn aggregation within the dopaminergic neurons of the substantia 
nigra by Betarbet et al., 2000 [234]. Rotenone, as the name implies, is a naturally forming 
rotenoid, that is lipid soluble and upon treatment induces mitochondrial dysfunction as a result 
of its ability cause uncoupling of mitochondrial complex 1 by inhibiting NADH-coenzyme Q 
oxidoreductase [235]. This process is thought to increase mitochondrial ROS and decrease 
glutathione levels; a primary protective antioxidant within the cell [236].   
Rotenone treated rats expressing human α-syn were shown to have exacerbated PD-like 
pathology including decreased motor function and large amounts of dopaminergic death within 
the substantia nigra [234, 237]. Additionally, the dopaminergic neurons from these rats were 
shown to have increased levels of the autophagic proteins LC3-II, Beclin-1, as well as, p62 a 
protein almost exclusive degraded via autophagy and therefore an indicator of general 
autophagic quality [234]. As a result, the study indicates that increased levels of both Beclin-1 
and LC3-II indicates that rotenone treatment increases autophagy, while also causing increased 
in dysfunctional autophagosomal degradation as indicated due to increased p62 levels [234] .  
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In addition to mitochondrial dysfunction and autophagic upregulation and dysfunction, 
rotenone treatment has been also been shown to decrease both the 20S and the 26S 
proteasome activity while not influencing their mRNA levels [238-239]. These results suggest 
that rotenone treatment also indirectly inhibits general proteasomal degradation and ubiquitin 
related proteasomal degradation albeit through an indirect mechanism that has yet to be 
elucidated [240]. 
Conclusion 
What mechanisms are important in regulating the secretion of pathological α-syn? And 
what role does exosomal α-syn play in the subsequent transmission of disease pathology among 
cells are two among many questions that are important in understanding synucleinopathies, 
such as PD. The unconventional secretion of α-syn among autophagic mechanisms is a relatively 
new discovery and a lot still needs to be elucidated; including whether the secretion of 
misfolded α-syn is generally beneficial or detrimental due to its association with increased 
clearance of α-syn within cells despite its role in the spreading of the disease pathology among 
its neighboring cells. Additionally, how exosomes play a role in the transfer of α-syn to 
associated brain regions and how doe autophagic mechanisms influence this process are 
questions that are just beginning to be investigated.  
 The next chapters will focus on our lab’s research on unconventional secretion of α-syn 
through autophagic mechanisms followed by the characterization of extracellular vesicles that 
contain α-syn. 
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CHAPTER THREE: 
MATERIALS AND METHODS 
Autophagic Mechanisms influence the unconventional secretion of  
Non-Monomeric Alpha-Synuclein 
Cell Culture. 
The SH-SY5Y human neuroblastoma cell-line and the HeLa immortalized cell-line were 
acquired from the American Type Culture Collection (ATCC). Cells were cultured in an incubator 
at 37C and 5% CO2 in Dulbecco's modified Eagle's Medium (DMEM) containing phenol red 
(Invitrogen), supplemented with the addition of 10% fetal bovine serum (FBS) (Hyclone), 10 
ug/ml ciprofloxacin hydrochloride, 100 IU/ml penicillin, and 100 ug/ml streptomycin.  
Over-expression of Alpha-Synuclein Dual Split Protein Construct. 
SH-SY5Y cells and HeLa cells were dually transduced to stably over-express both 
complements of our α-syn dual split protein construct (DSP)  using two individual lentiviral viral 
vector (pLVX) containing either α-syn-DSP-A or α-syn-DSP-B, each driven by a CMV promoter. 
Lentivirus was generated for transduction in HEK 293T cells transfected using the transfection 
reagent PEI with equal parts concentration of VSV-g, ΔNRF or psPax2, and pLVX-CMV-Alpha-
synuclein-DSP-A or pLVX-CMV-Alpha-synuclein-DSP-B plasmid. 48 hours post-transfection lenti-
viral particles were collected and purified from the 293T cells cultured media using a 0.45um 
Millipore syringe. The purified lenti-viral particles were then used to treat SH-SY5Y cells and 
spinoculated at 13°C for 2 hours at 1200 x g. The treated cells were then selected for those
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positive for the resulting DSP constructs by supplementing the previously mention DMEM with 5 
ug/ml puromycin. Cells were then sorted for GFP intensity by flow cytometry for further 
selection, to ensure the cells were dually expressing both complements of the α-syn DSP.  
CRISPR Knock-outs. 
The respective knock-outs/knock-downs in SH-SY5Y and HeLa cell lines were created 
using the LentiCRISPRv2 (Addgene plasmid 52961). The guide sequences used with the 
LentiCRISPRv2 were identified with the help of the CRISPR design tool (see 
http://www.crispr.mit.edu). Respective oligonucleotide guide sequences for ATG7:  5=-
CACCGTTTGAAGATTGCCTAGGGGG-3=, and Beclin-1: 5=-CACCGATCTGCGAGAGACACCATCC-3=, 
were annealed and then cloned into the Lenti-CRISPRv2 plasmid.  Lentivirus was generated for 
transduction in HEK 293T cells transfected using the transfection reagent PEI with equal parts 
concentrations of VSV-g, ΔNRF or psPax2, and the respective LentiCRISPRv2 plasmid. 48 hours 
post-transfection lenti-viral particles were collected and purified from the 293T cells cultured 
media using a 0.45um Millipore syringe. The purified lenti-viral particles were then added to our 
stable SH-SY5Y cells or HeLa α-syn DSP A&B cells and spinoculated at 13°C for 2 hours at 1200 x 
g. The transduced SH-SY5Y or Hela cells were then selected under hygromycin (Hyclone) and cell 
lysates were acquired for genomic knockout assessment via Western blot. 
Western blotting & Western Antibodies. 
Western blot cell lysates were acquired by lysing cells in NP-40 lysis buffer composed of 
100mM Tris pH 8.0, 1% NP- 40, and 150 mM NaCl with the addition of the protease inhibitor 
cocktail (Roche) for 30 minutes on ice. Afterwards, the lysates were centrifuged for 10 minutes 
at 14,800g and the supernatant collected. Collected supernatants’ protein concentrations were 
measured by the Pierce BCA protein assay kit (Thermo Scientific) and protein was equally loaded 
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and ran on a 10% polyacrylamide gel for SDS-polyacrylamide gel electrophoresis (SDS-PAGE). 
After separation, the proteins were then transferred to a nitrocellulose membrane (Bio-Rad). 
The nitrocellulose membranes were treated with respective primary antibodies overnight; 
Rabbit ATG7 (Invitrogen #PA5-35203) 1:350; Beclin-1 (Cell Signaling #3738) 1:1000; Tubulin 
1:200, diluted in powdered milk block solution 5g/50mL TBST. Primary antibodies were then 
washed and then subjected to their corresponding Horseradish Peroxidase (HRP) (Thermo 
Scientific) conjugated antibodies. HRP conjugated antibodies were then detected using 
SuperSignal West Femto Chemiluminescent Substrate (Thermo Scientific). Chemiluminescence 
levels were analyzed by using the FlourchemE Imaging System (Protein Simple). 
Luciferase Plate reading and Drug Treatments. 
SH-SY5Y α-syn DSP A&B Cells or HeLa α-syn DSP A&B Cells were equally plated in 24-well 
at a density of 65,000-210,000 per well depending on the experiment. The cells were then 
treated with DMSO vehicle of .5uL/500ul, Rapamycin 100uM, Bafilomycin-A1 100 nM, MG 132 
1mg/ml, Trehalose 100mM, 3-Methyladenine (5mM), or Rotenone 1um. 
The cell cultured medium was then collected 24 hours later and centrifuged at 4C for 5-
10 minutes and 12,000g. Afterward, the supernatant was collected and plated in triplicate at 
50ul per well, in a 96-well, for a luciferase assay via Veritas microplate luminometer (Turner 
Biosystems).  The Veritas (version 1.9.2) software was used in tandem with Veritas microplate 
luminometer in which the standardized Renilla Luciferase reading protocol was utilized. 
Depending on the experiment 50-100ul of Coelenterazine (NanoLight) solution was added via 
machine administration 
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Imaging Based Growth Rate Assessment in Tandem with Luciferase Plate Reading. 
After counting by hemocytometer, 60,000-75,000 cells were added to each well of a 24-
well plate containing fibronectin (sigma) treated coverslips and allowed to adhere for 4 hours in 
500ul of DMEM cultured medium. After 4 hours, the cultured medium was replaced with DMEM 
supplemented with either DMSO .5ul/500ul or bafilomycin-A1 100mM. The cultured medium 
was collected 24 hours later for Luciferase Assay and was subjected to the same methodology as 
described previously. Simultaneously, coverslips were collected and treated with fixative 
solution immediately before treatment and immediately after the 24hrs cultured medium was 
collected. The fixative solution was composed of 3.7% formaldehyde (Polysciences) and .1 M 
PIPES buffer solution for 5 minutes.  The coverslips were stained with Dapi in PBS for 20 minutes 
and were imaged by the on a DeltaVision wide field fluorescent microscope (Applied Precision, 
GE) outfitted with a digital camera (CoolSNAP HQ; Photometrics), while using a 1.4 numerical 
aperture, and 60× objective lens.  After their acquisition, the images were stitched together and 
deconvolved using the SoftWoRx deconvolution software (Applied Precision). The final stitched 
and deconvolved images were then analyzed on Bitplane: Imaris software version 7.6.4 
Statistical Analysis.  
All statistical analyses were done and graphs were generated using GraphPad Prism 
version 5.00 or 6.00 (GraphPad Software, Inc.). All data shown was analyzed using two-way 
ANOVA with Tukey’s post-hoc test and depicts the standard error of the mean unless otherwise 
specified. 
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The Novel Characterization of Preformed Fibrillar Alpha-Synuclein’s Association with 
Extracellular Vesicles on a Single Vesicle Level 
Cell Culture. 
The SH-SY5Y human neuroblastoma cell-line was acquired from the American Type 
Culture Collection (ATCC). Cells were cultured in an incubator at 37C and 5% CO2 in Dulbecco's 
modified Eagle's Medium (DMEM) containing phenol red (Invitrogen), supplemented with the 
addition of 10% fetal bovine serum (FBS) (Hyclone), 10 ug/ml ciprofloxacin hydrochloride, 100 
IU/ml penicillin, and 100 ug/ml streptomycin.  
Over-Expression of S15 mCherry Construct. 
For extracellular vesicle visualization experiments, SH-SY5Y cells were transduced to 
stably over-express S15-mCherry using a lentiviral viral vector (pLVX) containing our S15-
mCherry construct and driven by a CMV promoter. Lentivirus was generated for transduction in 
HEK 293T cells transfected using the transfection reagent PEI with equal parts concentration of 
VSV-g, ΔNRF or psPax2, and pLVX-CMV-S15-mCherry plasmid. 48 hours post-transfection lenti-
viral particles were collected and purified from the 293T cells cultured media using a 0.45um 
Millipore syringe. The purified lenti-viral particles were then used to treat SH-SY5Y cells and 
spinoculated at 13°C for 2 hours at 1200 x g. The treated SH-SY5Y cells were then selected for 
those positive for the resulting S15 mCherry by treating supplementing the previously mention 
DMEM with 5 ug/ml puromycin (Hyclone).  
Alpha-Synuclein Aggregation and Labeling. 
 For the extracellular vesicle visualization experiments, recombinant α-syn aggregates 
were created via a constant shaking of purified α-syn monomers on a table-top shaker at 200 
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rpm (Benchmark: incu-shaker mini)  for 7-10 days. The purified α-syn monomers were shaken at 
a concentration of 5 mg/ml and a constant temperature of 37°C in 20 mM Tris-Cl, pH 7.4. After 
the 7 days, A-syn aggregate were labeled were labeled with DyLight™ 488 NHS-ester 
fluorophores (ThermoFisher). Prior to α-syn treatment, α-syn fibrils were sonicated for 30 
seconds. Sonicated fibrils of α-syn were confirmed by EM (see Effects of Serine 129 
Phosphorylation on A-Synuclein Aggregation, Membrane Association, and Internalization).   
Extracellular Vesicle Collection. 
S15 mCherry SH-SY5Y Cells were plated in equal amounts at ~40% confluence within a 
60mm tissue culture dish and  were left untreated or treated with labeled sonicated  α-syn 
aggregates for 24 hours in DMEM at a concentration of 100nM, Afterwards, the cell cultured 
medium was removed and the cells were gently washed.  Fresh medium was added and collect 
72 hours later; the cells were given fresh medium and cultured medium was recollected again 
48 hours after the last medium change.   
Immunofluorescent staining and Preparation for Extracellular Vesicles.  
For the extracellular vesicle visualization experiments, 1mL of cultured medium was 
spinoculated at 13°C for 2 hours at 1200 x g onto glass coverslips and subsequently fixed with a 
solution of 0.1 M PIPES with 3.7% formaldehyde (Polysciences) for 5 minutes. Immediately after 
fixation, cells were incubated with one of four possible primary antibodies, mouse anti-CD9 (BD 
Pharmigen #555370), mouse anti-CD63 (BD Pharmigen #5556019), mouse anti-CD81 (BD 
Pharmigen #555675), or rabbit anti-Lamp1 antibodies (Abcam #24170), in a PBS block solution 
supplemented with 10% normal donkey serum (NDS), and 0.01% NaN3 for 1 hours. The 
extracellular vesicles were then subjected to their respective secondary donkey antibody 
conjugated to Alexa fluorophore 647; anti-mouse 647-conjugated or donkey anti-rabbit 647-
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conjugated secondary antibody at a concentration of 1:400, for 20 minutes diluted in the same 
PBS block solution supplemented with 10% (NDS), and 0.01% NaN3.  
Wide-field Fluorescence Deconvolution Microscopy and Analysis. 
Extracellular vesicle images were taken on a DeltaVision wide field fluorescent 
microscope (Applied Precision, GE) outfitted with a digital camera (CoolSNAP HQ; Photometrics), 
while using a 1.4 numerical aperture, and 60× objective lens. 25-30 images were taken from 
different locations on the cover-slip to create a representative population. The resulting 
collected images were deconvolved after their acquisition with the SoftWoRx deconvolution 
software (Applied Precision). The deconvolved images were then analyzed on Bitplane: Imaris 
software version 7.6.4, where the spots algorithm was built around either the S15 signal or α-
syn signal and the maximum fluorescence intensity found within these spots was then analyzed.   
All acquired images were subjected to the same spots signal algorithm via the Batch Coordinator 
tool (Bitplane) to each respective signal. Images with statistical outlying levels of signal were 
subjected to individual analysis and thrown out if deemed non-representative.  
Statistical Analysis.  
All statistical analyses were done using Microsoft Excel while the graphs were created 
using GraphPad Prism version 5.00 or 6.00 (GraphPad Software, Inc.).  
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CHAPTER FOUR: 
AUTOPHAGIC MECHANISMS INFLUENCE THE UNCONVENTIONAL SECRETION OF NON-
MONOMERIC ALPHA-SYNUCLEIN 
Introduction: Verification of Methodology 
Autophagy is one of the primary degradative pathways within the cell.  However, in the 
past decade, autophagy’s role has expanded past the scope of purely degradation and has been 
linked to the unconventional secretion of several proteins [9, 92, 94, 124, 173]. Furthermore, 
dysregulation or modulation of autophagic activity can further influence the secretion of these 
proteins. Among these proteins are IL-1β and the neurodegenerative associated proteins α-syn 
and Aβ. 
Several studies have shown that chemical dysregulation of autophagic mechanisms 
influenced the secretion of α-syn. In one specific example by Ejlerskov P et al. 2013, when PC12 
cells over-expressing α-syn were treated with the autophagic initiators rapamycin or trehalose, 
an increase in α-syn secretion was observed [9]. Additionally, they found that when cells over-
expressing both A30P α-syn and p25α, a protein important in the polymerization of 
microtubules and anterograde microtubule trafficking, were treated with the autophagic 
inhibitor 3-MA it resulted in a decrease in α-syn secretion [9]. These results were recapitulated 
when they knocking down the essential autophagic protein, ATG5 by siRNA within PC12 cells 
over-expressing the familial mutant variant of α-syn A30P, which also resulted in a decreased 
secretion of α-syn [9].  Therefore, based on these observations, increasing autophagic activity
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positively increased α-syn secretion while decreasing autophagic activity by inhibiting the 
autophagophore formation and elongation decreases α-syn secretion.   
Seemingly in contrast to the previously stated conclusion, several studies have found 
that the autophagic inhibitor, bafilomycin-A1 (BAF-A1), was also able to positively influence α-
syn secretion.  However, bafilomycin-A1’s mechanism of action varies from 3-MA’s mechanism 
of action or the mechanism associated with the depletion of ATG5, in that bafilomycin-A1 is a 
late phase inhibitor of autophagy. Rather influencing the autophagophore formation or 
elongation, bafilomycin-A1 inhibits the acidification and fusion of the lysosome with the 
autophagosome [189-190]. As a result, bafilomycin-A1 treatment increases the accumulation of 
autophagosomes [9]. Therefore, it has been speculated that simply increasing autophagic 
activity is not the only driving mechanism behind autophagic induced α-syn secretion. Rather, 
increased autophagic activity, as well as, the dysregulation of the degradative process also also 
influences α-syn’s secretion.  
Therefore, we hypothesized that if autophagophore formation is an essential 
component to α-syn secretion then inhibition of its formation would result in decreased 
secretion of our α-syn construct. However, if autophagy is inhibited by preventing the fusion of 
the autophagosome with the lysosome, then an increase in α-syn secretion will still occur due to 
the cell’s attempt to clear the accumulating undegraded cargo within the autophagosomes. 
Additionally, if we increase autophagic activity then we should see an increase in our constructs 
secretion based on the results observed by others [9].  To test these hypotheses, we created a 
SH-SY5Y cell-line with α-syn tethered to both halves of our dual-split protein construct (DSP).  By 
creating our SH-SY5Y α-syn DSP A&B cell-line that expresses α-syn with halves of our GFP-renilla 
luciferase dual-split protein construct we our able to measure α-syn that corresponds closer to 
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the pathogenic state as the enzymatic activity of measured luciferase must be non-monomeric.  
This is one of the first examples of this model being used to measure α-syn secretion. 
Experimental Design: Verification of Dual-Split Protein α-syn Construct 
Luciferase Plate reading and Drug Treatments. 
SH-SY5Y α-syn DSP A&B Cells Cells were equally plated in 24-well at a density of 65,000-
210,000 per well depending on the experiment. The cells were then treated with DMSO vehicle 
of .5uL/500ul, Rapamycin 100uM, Bafilomycin-A1 100 nM, Trehalose 100mM, 3-Methyladenine 
(5mM). All cells were cultured in a total of 500ul of DMEM for 24hours regardless of treatment 
condition. The cell cultured medium was then collected 24 hours later and centrifuged at 4C for 
5-10 minutes and 12,000g. Afterward, the supernatant was collected and plated in triplicate at 
50ul per well, in a 96-well, for a luciferase assay. Depending on the experiment 50-100ul of 
Coelenterazine (NanoLight) solution was added via machine administration. Each experiment 
was repeated three separate times unless specified otherwise. 
Results: Verification of Methodology 
Before testing whether non-monomeric α-syn secretion was dependent on autophagic 
mechanisms we first created are SH-SY5Y α-syn DSPA&B cell-line by dually transducing WT SH-
SY5Y cells with the aforementioned constructs.  Cells were grown up under puromycin selection 
and then a homogenous population was selected via flow cytometry based on GFP intensity 
(Figure 1). By selecting the DSP cells above a specific GFP intensity, we hoped to rule out the 
possibility of singly transduced cells or cells with imbalanced transduction levels of each of the 
respective α-syn DSP compliments. 
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After the selection process, cells were allowed to grow for a few passages to insure 
stability among experiments. These DSP constructs were first created and published by the 
Matsuda lab and utilize corresponding halves of a renilla luciferase and green fluorescent 
protein (GFP). Individually each half is non-functional, however upon complementation, the 
complementing halves come together and the renilla luciferase and GFP regain function. 
 
Figure 1. Cartoon representation of how the α-syn DSP A&B construct functions and the selection of the 
SH-SY5Y α-syn DSP A&B cell-line. A) Cartoon indicating how the α-syn dual-split protein constructs A and 
B work. Individually neither construct A nor B functions. However, upon complementation, the construct 
regains GFP and Renilla Luciferase activity. B) Flow cytometry for the selection of GFP positive cells of high 
intensity. The selection was conducted to select for a homogenous cell population in which cells 
transduced both DSP constructs A and B in relative amounts to get the desired intensity. 
By tethering each respective, corresponding half of the DSP construct to α-syn and over-
expressing both complements within the same cell, we are able to measure DSP 
complementation by either the renilla luciferase activity or visualize the complementation via 
the fluorescence of the GFP (example shown in Figure 5). Increases in measurements indicates 
that the increased complementation of dual-split protein α-syn  counterparts are occurring 
which one would expect to find within aggregated, pathological α-syn oligomers; in contrast to 
non-pathological α-syn which is thought to be found primarily in its monomeric form, as stated 
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early within the review of the literature. Therefore, this DSP α-syn model should more 
accurately represent pathogenic α-syn in contrast to simply a luciferase-α-syn construct.  
To verify our DSP model was functioning the way we intended, we first treated with 
known chemical activators of autophagy, rapamycin and trehalose, as well as, the known 
chemical inhibitors of autophagy, 3-methyladenine and bafilomycin-A1, in which other studies 
have shown influence the secretion of α-syn [9]. Cells were exposed to each of the respective 
conditions for 24 hours before having their cell culture medium collected and then plated in 
triplicate for a luciferase assay. Based on previous findings, we would expect that autophagic 
activators rapamycin, trehalose, as well as, the autophagic inhibitor bafilomycin-A1 should 
increase complemented α-syn DSP secretion; while in contrast, 3-MA treatment should 
decrease complemented DSP α-syn secretion, if our model is functioning properly. 
Similar to results found by previous studies, we found that when our SH-SY5Y α-syn 
DSPA&B cells were treated with the known activators of autophagy, rapamycin and trehalose, 
we saw a significant fold increase, which corresponded to roughly 3x amount of complemented 
DSP secretion when compared to the DMSO vehicle control (Figure 2). In addition, we found 
that when our cells were treated with the known late phase autophagic inhibitor bafilomycin-A1 
we also saw a significant increase of roughly 3x fold in complemented DSP secretion while in 
contrast, when cells were treated with autophagic inhibitor, 3-methyladenine, which inhibits 
autophagy by directly inhibiting the autophagophore specific class III PI3K, we did not see any 
significant change in our complemented DSP signal (Figure 2). These results indicate that our 
DSP-α-syn model functions similarly to how we would have hypothesized and provides evidence 
verifying the authenticity of our model. Furthermore, it supports the idea that increased 
autophagophore formation is an important part of non-monomeric α-syn secretion.  
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Figure 2. Autophagic activators and inhibitors influence DSP α-syn secretion. SH-SY5Y cells expressing 
both α-syn DSP A&B constructs were either treated with DMSO (.5uL/500uL), 3-MA (5mM), Bafilomycin-
A1 (100 nM), Trehalose (100mM), or Rapamycin (.1mM) for 24 hours. The cell culture medium was then 
collected and plated in a 96 well plate in triplicate for a renilla luciferase reading was taken with the 
automated addition of 66uL of coelenterazine substrate. Each treatment condition was replicated 3 
separate times.  Data was analyzed by two-way ANOVA with Tukey’s post-Hoc test. Error bars depict 
standard error of the mean. 
Introduction: ATG7 and Beclin-1 Knock-Down 
Next, we investigated how CRISPR-CAS9 knock-down of the essential autophagic 
proteins, ATG7 and Beclin-1, influenced the secretion of our complemented α-syn DSP 
construct. ATG7 is an essential autophagic protein that plays a role in both the formation and 
the elongation of the autophagophore [103].  ATG7 acts as an E1 ubiquitin like protein and plays 
a role in forming of the primary ATG complexes, as well as, part of the core ATG proteins 
essential to LC3 conjugation [103]. In the ATG-LC3 conjugation system, ATG7 initiates the 
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shuttling of LC3-I to the autophagophore, as well as, later in the elongation process shuttling 
GABARAP [83]. Similarly, ATG7 also shuttles ATG12 to ATG10 thereby assisting in forming the 
ATG12-5-16 complex, that converts LC3-I into the active LC3-II [103, 123-126]. Without LC3, an 
autophagophore cannot go through elongation [103, 123-126].   
Based on our previous findings reported by others showing decreased α-syn secretion 
occurred when ATG5 was depleted by siRNA knock-down, we would expect, similarly, that 
decreased secretion of complemented DSP-α-syn should be observed [9].   
While Beclin-1 is also essential to autophagy, it functions in distinct manner to promote 
the formation of the autophagophore [116-121].  Beclin-1 is enzymatically inactive but has 
several binding domains, including a domain that allows it to bind to the class III PI3K (VPS34) 
which allows it to recruit the other proteins that are essential to the formation of the Beclin-1 
complex [118].  Therefore, by knocking-out Beclin-1 we would expect similar results to those 
observed when cells are treated with the class III PI3K inhibitor, 3-MA; decreased secretion of 
complemented α-syn.    
Experimental Design: ATG7 and Beclin-1 knock-down 
SH-SY5Y α-syn DSP A&B Cells or HeLa α-syn DSP A&B Cells were equally plated in 24-well 
at a density of 65,000-210,000 per well depending on the experiment. The cells were then 
treated with DMSO vehicle of .5uL/500ul or Bafilomycin-A1 100 nM, Trehalose 100mM. All cells 
were cultured in a total of 500ul of DMEM for 24hours regardless of treatment condition. The 
cell cultured medium was then collected 24 hours later and centrifuged at 4C for 5-10 minutes 
and 12,000g. Afterward, the supernatant was collected and plated in triplicate at 50ul per well, 
in a 96-well, for a luciferase assay. Depending on the experiment 50-100ul of Coelenterazine 
50 
 
 
 
(NanoLight) solution was added via machine administration. Each experimental condition was 
repeated 3-7 separate times. 
Results: ATG7 and Beclin-1 Knock-Down 
To investigate whether depletion of ATG7 influenced the secretion of our α-syn DSP 
construct we used CRISPR-CAS9 technology in an attempt to knock-out the ATG7 gene.  We tried 
to knock-out ATG7 within our SH-SY5Y α-syn DSP cell-line several times with a couple different 
guide sequences; each time resulted in seemingly lethal knock-out and we were unable to 
successfully introduce the knock-out into our stable α-syn DSP cell-line.  As results, we moved to 
knocking out ATG7 within our HeLA α-syn DSP cell-line.  We were able to successfully achieve a 
stable heterogeneously knock-down of ATG7 within a population of HeLa α-syn DSP cell-line as 
indicated by our western blot (Figure 3, A).  
To investigate whether α-syn secretion was influenced as a result of our ATG7 knock-
down we treated control HeLa cells and the ATG7 knock-down cells with either DMSO vehicle 
control or bafilomycin-A1, allowing us to control for any possible changes in growth rate, and 
differences in cell number between replicates of the two cell-lines. We choose bafilomycin-A1 
among our drugs for two reasons, it is the best documented to induce α-syn secretion and it has 
fewer off-target effects when compared to autophagic initiators trehalose and rapamycin. We 
found that when we normalized our bafilomycin-A1 results to their respective cell-line controls 
that a significant decrease in the fold change between the WT HeLa α-syn DSP cells was 
observed compared the ATG7 knock-down (Figure 2B).   
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Figure 3. HeLa ATG7 KO and WT DSP α-syn secretion: bafiolmycin-A1 treatment. A) Depicts the Western 
Blot confirming the knock-down of ATG7 within our HeLa cell-line that also has stabile expression of both 
our α-syn DSP A&B construct.  B) Shows the relative fold difference in complemented α-syn DSP A&B 
secretion among our WT HeLa α-syn DSP A&B cells and ATG7 KO HeLa α-syn DSP A&B. Each condition 
shows the relative fold change among the DMSO to bafilomycin-A1 treatment when compared to WT or 
ATG7 knock-down, respectively. Each treatment was replicated 8 times, where each replicate was plated 
in triplicate in a 96-well and the automated injection of 50-100ul coelenterazine was added with respect 
to the replicate. Data was analyzed by two-way ANOVA with Tukey’s post-Hoc test. Error bars depict 
standard error of the mean. 
In contrast to our attempts to knock-out ATG7, we were able to successfully and 
robustly knock-down Beclin-1 via CRISPR-CAS9 within our SH-SY5Y α-syn DSP cell-line and 
produce a stable population as confirmed by our western blot (Figure 3 A).  Similar to our HeLa 
knock-out cell line, we plated equal amounts of our WT SH-SY5Y α-syn DSP cell-line and our 
Beclin-1 SH-SY5Y α-syn DSP cell-line and either treated the cells with DMSO vehicle or 
bafilomycin-A1. We normalized the secretion relative light intensity values of the bafilomycin-A1 
to DMSO vehicle rule out the possibility of changes in growth experience between the 24 hour 
incubation periods with the respective treatments between the two cell-lines.  We found that 
there was a significant decrease in complemented α-syn DSP secretion between our Beclin-1 
knock-down variant and our WT α-syn DSP cell-lines when treated with bafilomycin-A1. 
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Therefore, both Beclin-1 and ATG7 appear to be important for the secretion of α-syn, in 
concurrence with Ejlerskov P et al., 2013, ATG5 observations indicating decreased α-syn 
secretion.  
 
 
Figure 4. SH-SY5Y Beclin-1 KO and WT DSP α-syn secretion: bafilomycin-A1 treatment. A) Depicts the 
Western Blot confirming the knock-down of Beclin-1 within our SH-SY5Y cell-line that also has stabile 
expression of both our α-syn DSP A&B construct.  B) Shows the relative fold difference in complemented 
α-syn DSP A&B secretion among our WT SH-SY5Y α-syn DSP A&B cells and Beclin-1 KO SH-SY5Y α-syn DSP 
A&B. Each condition shows the relative fold change among the DMSO to bafilomycin-A1 treatment when 
compared to WT or Beclin-1 knock-down, respectively. Each treatment was replicated 8 times, where 
each replicate was plated in triplicate in a 96-well and 50-100ul of coelenterazine was added with respect 
to the replicate. Data was analyzed by two-way ANOVA with Tukey’s post-Hoc test. Error bars depict 
standard error of the mean. 
Next, we investigated the differences in α-syn secretion while controlling for growth 
rate over a 24 hour period among our respective ATG7 knock-down HeLa α-syn DSP cell-line and 
its WT HeLa α-syn DSP cell-line counterpart, as well as, our Beclin-1 knock-down SH-SY5Y α-syn 
DSP cell-line and its WT SH-SY5Y α-syn DSP cell-line counterpart. The purpose of this experiment 
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was to show the relative light intensity results after controlling for growth rate. This allows for 
the accurate comparison among the DMSO condition between respective WT and KO cell-lines. 
Each cell type was counted and 60,000 of both HeLa cell variants and 75,000 of both SH-SY5Y 
cell variants were plated onto fibronectin coated cover-slips within a 24 well plate.  Cells were 
allowed to sit down for 4 hours and were then collected as time 0hrs or had their medium 
changed and treated with DMSO or bafilomycin-A1.  24 hours later the medium was collected 
for luciferase assay and the cells were fixed and stained for their nuclei via Dapi stain.  The cells 
from untreated condition at both 0 hours and the 24hrs DMSO treated were then imaged via 
fluorescent microscopy among the respective and WT and knock-downs.  Three separate 
stitched images were taken that resulted in the formation of a 5x5 panel of images, spanning a 
total of 550um in each direction. The images were deconvolved and the nuclei were counted at 
a constant Dapi brightness, with respective images being shown for each time point and cell 
variant (Figure 5).  The number of nuclei for each stitched 5x5 panel was then average among all 
three images and each condition was replicated a second time.   
We found no significant difference in growth rate among the cell-lines with respect to 
their knock-out and control.  Additionally, the number of cells at the 24 hours mark was roughly 
comparable between the ATG7 knock-down HeLa α-syn DSP cell-line and its WT HeLa α-syn DSP 
cell-line counterpart, as well as, our Beclin-1 knock-down SH-SY5Y α-syn DSP cell-line and its WT 
SH-SY5Y α-syn DSP cell-line counterpart as one would expect.    
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Figure 5. Representative images of cell growth rate among WT and ATG7 KO HeLa α-syn DSP and WT 
and Beclin-1 KO SH-SY5Y α-syn DSP.. The image shows representative stitched 5x5 image panel for 
untreated WT and ATG7 knock-down HeLa α-syn DSP cell-line and Beclin-1 knock-down SH-SY5Y α-syn 
DSP cell-line at both 0hrs and 24hrs. The total stitched distances is 550um in both the horizontal and 
vertical direction. Each cover-slip had 3 non-overlapping 5x5 image panels taken and the nuclei was 
counted at min intensity of 300 and a max intensity of 1500.  2 replicate cover-slips for each cell was 
taken for each respective time point.  
 
55 
 
 
 
 
Figure 6. Quantification of cell growth rates and raw luciferase intensity of the secreted complemented 
α-syn DSP construct. A&B) Shown in A&B are the average number of nuclei among the respective 
untreated cells at 0 and 24 hours for the HeLa α-syn DSP A&B WT and ATG7 KO and the SH-SY5Y α-syn 
DSP A&B WT and Beclin-1 KO cell-lines. The graphs show the standard deviation of from the mean values 
of the 2 replicates. C&D) the graphs shown in C&D show the raw RLU intensity of collected culture 
medium from each respective cells and treatments that correspond with the 24 hour DMSO condition 
shown from graph A&B which indicated no significant difference in cell growth or cell number occurred 
between time points. The data shows the standard deviation of the two replicates in which each replicate 
was plated in triplicate within a 96-well plate and subjected to an automated injection of 100ul of 
coelenterazine substrate as part of the renilla luficerase assay. Data was analyzed by two-way ANOVA 
with Tukey’s post-hoc test 
 
Additionally, the renilla luciferase readings among our untreated and bafilomycin-A1 
treated, with respect to WT and knock-down, had relatively comparable RLU values when 
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compared to our normalized fold change values reported previously (Figure 3&4). However, the 
untreated between both our ATG7 and Beclin-1 knock-down cell-lines trended toward having a 
decreased basal level of complemented α-syn DSP secretion although they were not significant.  
Additionally, the Beclin-1 knock-down bafilomycin-A1 treatment lost its significance when 
compared to its respective WT Beclin-1 knock-down DMSO treatment. This is likely due to the 
fact that only two replicates (due to time restrictions) being conducted but illustrates the 
differences between the WT and Beclin-1 knock-down α-syn DSP cell-lines.  
Introduction: MG 132 and Rotenone Treatment 
The ubiquitin proteasome system (UPS) is another one of the primary cellular 
degradative pathways. In addition to autophagy, the UPS is also important in the removal α-syn.  
Studies show, that upon inhibition of the proteasome, an increase in misfolded α-syn 
accumulates intracellularly [220-221]. This accumulation of α-syn results exacerbation of 
parkinsonian pathology. Furthermore, inhibition of the UPS is sensed by autophagic pathways, 
resulting in inhibition of mTOR1 and increased activation of AMPK, both of which upregulate 
autophagy [213-216].  This upregulation of autophagy is thought to occur in an attempt to 
compensate for proteasomal inhibition, and within the context of PD pathology, helps increase 
degradation of α-syn accumulations. However, others studies have shown that pharmaceutical 
inhibition of the proteasome by MG 132 treatment also results in an increase in α-syn secretion 
within PC12, rat adrenal medulla cells, over-expressing α-syn mutant A53T [221-222]. Therefore, 
we decided to investigate whether MG 132 would influence α-syn DSP secretion within our 
system. 
Finally, another drug we were interested in testing within our system is rotenone, a 
pesticide that has been associated with PD pathology [234]. Rotenone is primarily a 
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mitochondrial inhibitor; however, it has also been linked to indirect proteasomal inhibition by an 
unknown mechanism [234, 238-239]. Interestingly, the UPS system is important in the turnover 
of damaged mitochondria and its inhibition results in decreased clearance of damaged 
mitochondria [229]. Additionally, mitochondrial dysfunction and poor turnover of mitochondria 
results in an increase in ROS, which is thought to be a main contributor of PD pathology [223].  
Therefore, we would expect that rotenone would increase α-syn secretion due to an 
upregulation in autophagy from increased dysfunctional mitochondria and aggregate α-syn.  
Experimental Design: MG 132 and Rotenone Treatment. 
SH-SY5Y α-syn DSP A&B Cells Cells were equally plated in 24-well at a density of 65,000-
210,000 per well depending on the experiment. The cells were then treated with DMSO vehicle 
of .5uL/500ul, MG 132 .1mg/ml, or Rotenone 1um, respectively. All cells were cultured in a total 
of 500ul of DMEM for 24hours regardless of treatment condition. The cell cultured medium was 
then collected 24 hours later and centrifuged at 4C for 5-10 minutes and 12,000g. Afterward, 
the supernatant was collected and plated in triplicate at 50ul per well, in a 96-well, for a 
luciferase assay. Depending on the experiment 50-100ul of Coelenterazine (NanoLight) solution 
was added via machine administration. Each experiment was repeated three separate times 
unless specified otherwise. 
Results: MG 132 and Rotenone Treatment. 
To test whether rotenone or MG 132 influenced α-syn secretion, we used our SH-SY5Y 
α-syn DSP cell-line, we plate equal concentrations of cells and treated our cells with our DMSO 
vehicle control, MG 132, or rotenone.  We hypothesized that if we treated our cells with drugs 
that influenced α-syn aggregation then we would see increases in α-syn DSP complementation 
and that it would result in increased secretion of aggregate α-syn.   
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Upon collecting and testing of the cell culture medium by luciferase assay from the 
various conditions, we found that MG 132 resulted in significant ~5x fold increases in α-syn 
secretion when compared to the DMSO control (Figure 7). Additionally, rotenone treatment also 
resulted in a significant fold increase of complemented α-syn secretion of ~7x fold when 
compared to the control. Furthermore, the rotenone treated cells secreted significantly more 
complemented α-syn DSP when compared to MG 132. Therefore, based on our observed results 
non-monomeric α-syn secretion increases as a result of proteasomal inhibition by MG 132 as 
well as when mitochondrial dysfunction and indirect proteasomal inhibition occurs via rotenone 
treatment.  
 
Figure 7. Direct and indirect proteasome inhibitors influence the secretion of the complemented α-syn 
DSP construct. The graph depicts how the treatment of DMSO, MG 132, or Rotenone influenced the 
secretion of our complemented α-syn DSP construct from our SH-SY5Y α-syn DSP A&B cell-line. The graph 
shows the relative fold change intensity comparing each treatment to the DMSO control. Each treatment 
was replicated 3 times, where each replicate was plated in triplicate in a 96-well and the automated 
injection of 50ul coelenterazine was added. Data was analyzed by two-way ANOVA with Tukey’s post-Hoc 
test. Error bars depict standard error of the mean. 
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Discussion 
The goal of our study was to investigate how small molecule activators and inhibitors of 
autophagy, genetic depletion of important autophagic proteins, ATG7 and Beclin-1, proteasomal 
inhibition, and mitochondrial dysfunction influence the complemented secretion of our novel α-
syn DSP construct. By measuring the renilla luciferase enzymatic activity that only occurs upon 
DSP complementation, our goal was to more accurately model pathogenic α-syn secretion, 
associated with the oligomeric species α-syn.  In addition to looking at non-monomeric α-syn, 
another strength associated with our DSP model is the bioluminogenic substrate of renilla 
luciferase, coelenterazine, has some level of cell-membrane penetrance. This property of 
coelenterazine is particularly important as α-syn oligomers have been implicated to 
preferentially be included within the extracellular vesicles, such as exosomes [8]. In addition, 
autophagic dysregulation likely induces the secretion of both vesicle associated and naked, non-
vesicular species of α-syn. Therefore, by measuring the the renilla luciferase activity we are not 
unintentionally neglecting either naked or vesicular α-syn.  
We began by validating our model and hypothesized that if autophagophore formation 
is essential to our complemented DSP α-syn secretion, then inhibition of its formation would 
result in decreased secretion of our complemented α-syn construct. However, if inhibition of 
autophagic degradation, while preservation of autophagosome formation occurs, then we 
should observe an increase in secretion of our α-syn construct due to the cells attempt to clear 
the accumulating undegraded cargo.  Additionally, if we increase autophagic activity then we 
should see an increase in our constructs secretion due to α-syn being a natural target for 
autophagic secretion.   
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Therefore, if cells are treated with an autophagic activator, such as rapamycin or 
trehalose, or an autophagic inhibitor, such as 3-MA or bafilomycin-A1, as long as an increase in 
the formation or accumulation of autophagosomes due to inhibition of the degradation then we 
would expect an increase α-syn secretion to occur. Based on the results of Figure 2, we found 
that our hypothesis fit with our observations, when our cells were treated with autophagic 
activators rapamycin or trehalose, respectively. These results are particularly interesting as 
trehalose and rapamycin activate autophagy through different mechanisms [9]. 
Rapamycin causes an upregulation of autophagy through its inhibition of mTOR1 [151, 
153-155]. Rapamycin is membrane-permeable and upon entering the cell binds to and inhibits 
FKB12 [153-155]. This rapamycin-FKB12 complex then goes on to bind to mTOR1, resulting in 
mTOR1 inhibition and subsequently an upregulation in starvation induced autophagic activity 
[153-155].  Additionally, recent studies have found that prolonged or high-dosage rapamycin 
treatment results in an inhibition of mTOR2 [158-160].  While very little is known about what 
cascades mTOR2 is responsible for regulating, it is thought that chaperone-based autophagy is 
among them [162]. Conflicting evidence exists for whether rapamycin is capable of inducing α-
syn secretion. In our study we treated with a large amount of rapamycin, apossible explanation 
for why we saw such a profound increase in α-syn secretion may be due our large rapamycin 
dosage.  Another possible explanation is that because our system monitors α-syn secretion 
within the context of non-monomeric variations, we are seeing increases in aggregated α-syn 
release which has been shown to be partially degradative resistant [244]. It seems plausible that 
when a cell is unable to properly degrade α-syn via autophagic mechanisms, the resulting 
autophagosome undergoes secretion instead. The results that we, and others, have observed 
indicate that bafilomycin-A1 treatment causes an increased in autophagic secretion of α-syn by 
causing an increased accumulation of autophagosomes. Furthermore, if increased α-syn 
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accumulation had begun to occur in a cell, autophagy may already be occurring, resulting in 
autophagic dysregulation and increased secretion.  
In contrast to rapamycin, trehalose is thought to activate autophagy through a 
mechanism that is independent of mTOR1 [168]. Although the exact mechanism has not been 
identified, it is thought trehalose increases autophagy by somehow stimulating AMPK, which 
results in an increase of quality control autophagy rather than starvation induced autophagy 
[168]. In quality control autophagy specific targets, such as α-syn aggregates, are identified for 
degradation via post-translational ubiquitination linkages [148-150, 168, 170].  This quality 
control based activation of autophagy by trehalose explains why we see an increase in α-syn 
being targeted for autophagy and an increase in α-syn secretion. Moreover, others have seen 
that trehalose causes an increase α-syn secretion which is consistent with our findings [9]. 
In addition to our autophagic activators, we found that 3-MA, the early autophagic 
inhibitor, and bafilomycin-A1 our late phase autophagic inhibitor also met our hypothesized 
criteria; if autophagophore formation is an essential component to α-syn secretion then 
inhibition of its formation would result in decreased secretion of our α-syn construct. However, 
if inhibition of autophagic degradation, while preservation of autophagosome formation occurs, 
then we should observe an increase in secretion of our α-syn construct due to the cells attempt 
to clear the accumulating undegraded cargo. 
Several studies have found that bafilomycin-A1 was able to induced increased levels of 
α-syn secretion [8-9, 49, 88]. While bafilomycin-A1 is an inhibitor of degradative autophagy, it 
does not alter autophagosome formation but rather indirectly inhibits autophagy through 
lysosomal dysregulation, as stated previously [189-190]. Therefore, it is been proposed that the 
reason that bafilomycin-A1 causes an increase α-syn secretion is due to increased accumulation 
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of autophagosomes that are unable to go through degradation [8]. This accumulation of 
impotent autophagosomes results in disruption of the normal degradative autophagosomal 
pathway and causes an increase autophagosomes going through the secretory pathway instead.   
In contrast, secretion of α-syn is dependent on autophagosome formation and the 
treatment of 3-MA has been demonstrated to decrease α-syn secretion, as previously stated in 
our introduction, by Ejlerskov P et al., 2013. We found that when we treated our cells with 3-MA 
no observable change in α-syn secretion was observed. A possible explanation for the difference 
between our results and the results that Ejlerskov P et al., 2013, observed could be due to their 
co-transduction with P25α and mutant α-syn A30P while we used our α-syn DSP model. 
Additionally, the temporal differences of 3-MA treatment may also provide an explanation. 
However, our results support the idea that autophagic activation is important for the secretion 
of α-syn. 
To follow up on our 3-MA data which indicates the importance of autophagophore 
formation, we next looked at how genetic depletion of ATG7 via CRISPR-CAS9 knock-out 
influenced secretion of our α-syn DSP construct. We saw a significant decrease in secretion of 
our complemented α-syn construct within the context of bafilomycin-A1 treatment, which 
indicates that autophagophore elongation is important for α-syn secretion.  Additionally, are 
results are indirectly supported by Ejlerskov P et al., 2013, data which showed that siRNA knock-
down of ATG5, substantially decreased α-syn secretion.  
Furthermore, to expand on this previous stated idea, Aβ secretion has also been linked 
to autophagic regulation [99]. In support of the similarities between Aβ and α-syn secretion: In 
wild-type primary neurons, Aβ secretion increased when cells were treated with rapamycin; 
which corresponds with our observed results [99].  Additionally, it has been shown that Aβ 
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secretion decreases within wild-type primary neurons treated with the Beclin-1 complex 
autophagic inactivator, spautin-1 and increases with the treatment of rapamycin [99]. 
Furthermore, when a neuron specific ATG7 knock-out was introduced into Aβ mice, it was found 
that a decrease in Aβ secretion was observed [99].  These, same mice also had increased Aβ 
accumulation within their perinuclear regions [99]. 
Drawing on our ATG7 knock-out results indicating that proper formation and elongation 
of the autophagophore influenced complemented α-syn DSP secretion, we hypothesized that 
knocking out Beclin-1 by CRISPR-CAS9 would also result in decreased complemented α-syn DSP 
secretion. Concurrent with what we observed with our ATG7 knock-out cells, we found that 
when we treated our Beclin-1 knock-out cells with bafilomycin-A1 we saw a significant decrease 
in α-syn secretion when compared to our control, providing further evidence of autophagy’s 
role in α-syn secretion.  As far as we know, this is the first demonstration of Beclin-1’s role being 
fundamental to influencing α-syn secretion but fits the expected results associated with Aβ and 
spautin-1 treatment. 
In addition to directly modifying the autophagic mechanism via drug treatment or 
genetic depletion, we were also interested in investigating the role that proteasomal inhibition 
had on α-syn secretion. It is well documented that inhibition of UPS results in an upregulation of 
autophagic activity as compensatory mechanism [213-216]. For example, when the S26 
proteasome is inhibited within hippocampal neurons a decrease in GSK-3β is observed [215]. 
Decreased GSK-3β activity results in an increase in AMPK which as previously mentioned, 
increases quality control autophagy [215].  Furthermore, it has been shown that the UPS serves 
to help alleviate the burden of accumulating α-syn aggregates.  Our data suggests that an 
increase in complemented α-syn secretion occurred upon UPS inhibition as result of MG 132. 
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Although more data is necessary, a logical explanation for this observed increase may be due to 
an upregulation in autophagic activity in an attempting to clear the α-syn through autophagy 
due to inhibition of the UPS. 
We also observed an increase in α-syn secretion when we treated our SH-SY5Y α-syn 
DSP cells with the mitochondrial inhibitor and indirect proteasomal inhibitor of rotenone. As 
previously stated, proteasome inhibition decreases α-syn degradation and causes upregulation 
of autophagy [213-26]. However, the UPS has also been shown to be particularly important in 
the turnover of damaged mitochondria [233]. Inhibition of the proteasome also results indirectly 
in increasing cellular ROS due to damaged mitochondria accumulation which has been 
associated with PD pathology [229-231, 233].  Therefore, we believe that rotenone increases α-
syn secretion via a combination of effects including its ability to cause proteasomal inhibition 
induced increase in autophagic activity and reduce mitochondrial turnover; as well in part due 
rotenone’s ability to cause inhibition of mitochondrial function leading to subsequent increases 
in cytoplasmic ROS generation. This perfect storm of problems likely also plays a part in α-syn 
aggregation which explains the very high fold increase in α-syn DSP secretion.  These results are 
in agreeance with with those reported by Jang et al., 2010 [49]. 
Future Directions 
Now that we have successfully verified our α-syn DSP construct cell model, a lot of 
opportunities exist due to the flexibility associated with the dual protein activity of the renilla 
luciferase and GFP construct.  One option we are interested in pursuing is to investigate the 
differences associated with α-syn DSP puncta within our cells lines among the different 
autophagic treatment conditions. Our preliminary experiments indicate changes in DSP puncta 
being visualized within our cells upon drug treatment conditions, which can be further 
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augmented by the treatment of sonicated preformed fibrillar α-syn . Additionally, we are in the 
process of getting a true homogenous knock-out for our respective ATG7 and Beclin-1 cell-lines 
and further verification of our secretion results. Additionally, ideally we would be interested in 
doing these knock-outs within other more relevant cell-lines, such as primary neurons. Another 
opportunity to investigate is to look at the GFP within the secreted EVs by our DSP cell-line and 
investigate the changes specifically associated autophagic secretion upon induction by our small 
molecule treatments utilizing the methodology that will be explained in detail in the next 
chapter.  
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CHAPTER FIVE: 
THE NOVEL CHARACTERIZATION OF PREFORMED FIBRILLIAR ALPHA-SYNUCLEIN’S ASSOCIATION 
WITH EXTRACELLULAR CELLULAR VESICLES ON A SINGLE VESICLE LEVEL 
Introduction 
Exosomes are one of the subtypes of the total extracellular vesicle (EV) population and 
range from 30nm to 150nm in size [55-58].  Exosome biogenesis occurs as part of the endo-
lysosomal pathway, where exosomes were once the intraluminal vesicles (ILVs) within a 
multivesicular body (MVB) [55-57, 59]. Upon MVB fusion with the plasma membrane the ILVs 
undergo extracellular exocytosis where they are now considered exosomes [55-57].  Initially the 
exosomes released as part of MVB and plasma membrane fusion were thought to be the cells 
unwanted waste [55]. However, it is now recognized that exosomes serve an import 
physiological role in intercellular communication through the transference of specific cargoes. 
Among these cargoes are RNA, protein, and lipids which can have dramatic effects to influence 
the receipt cells [60-65]. As a result of the reorganization late endosomes undergo before they 
can begin to form ILVs and progress to MVBs, they become enriched with tetraspaninin 
proteins, a subfamily of proteins that organize membrane microdomains by forming clusters 
that interact with a large variety of cytosolic and transmembrane signaling proteins [55-56, 66]. 
After the enrichment process, cargo is sorted into ILVs by the ESCRT protein complexes. As a 
result the tetraspanins, which are broadly expressed among tissues, as well as, specific highly 
conserved ESCRT proteins are recognized as canonical exosomal markers [55-56].  
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In addition to exosomes serving a role in intercellular communication, they are also 
associated with disease propagation. One of the predominant hypotheses for cell-to-cell 
transmission of PD pathology is through the release and uptake of α-syn associated exosomes 
[8]. Tissue culture studies have shown that WT α-syn can be transmitted among cells in an 
exosome dependent capacity. In addition, α-syn transferred via exosomes is capable of inducing 
aggregation within the recipient cell [8]. Recent in vivo evidence found that pathological α-syn 
species could be purified from the exosomes from CSF of patients with both DLB and PD [59], 
thus indicating that exosomes play a role in the spread of synucleinopathy pathology.  
Furthermore, it was demonstrated by Danzer et al., 2012, that transmission of exosome 
associated α-syn oligomers, the α-syn variant thought to be responsible for neurotoxicity, are 
taken up within the cell preferential and were more likely to induce cell death than naked, non-
vesicular α-syn oligomers. Indicating that transmission of α-syn via exosomes is more neurotoxic 
and potentially more pathogenic.  
While exosomes have been shown to play a role in the transmission of cargoes, a 
growing body of evidence also suggests that exosomes are not a homogenous population and 
that specific subpopulations exist among them. Therefore, the goal of our study was to develop 
a new methodology that allows for the characterization of EVs on a single EV level. To do this we 
formulated a novel methodology that utilizes wide-field deconvolution microscopy and 
immunofluorescent staining in tandem with imaging analysis software to identify individual EV 
contents through protein co-localization analysis. We then validate our methodology by 
investigating whether sonicated preformed fibrils (PFFs) of α-syn specifically associate one of 
our tested canonical exosomal markers: CD9, CD63, CD81, and LAMP1.  As far as we know, these 
techniques are currently not utilized within the exosome field. Furthermore, this adaptation of 
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techniques represents a strong alternative to those currently used that rely on first isolating 
specific fractions of EVs via ultracentrifugation and then looking at total isolated EV proteins due 
to the intrinsic nature of the readily used western blot, ELISA, and immunoblot methodology.  
Experimental Design 
We created our stable mCherry S15 SY5Y cell-line by transducing wild type SH-SY5Y cells 
with S15 mCherry vector that resulted in the stable expression of the S15 mCherry construct 
within these cells; hence forth referred to simply as S15 SH-SY5Y cells. We plated equal 
concentrations of our S15 cells into two 60mm dishes at ~40% confluency. Cells were either left 
untreated or treated with Alexa 488 fluorescently stained α-syn (PFFs) at concentration of 
100nm. 24 hours after PFF treatment, both conditions cultured medium was replaced with 4mL 
of fresh DMEM. 72 hours later (96 hours after the initial PFF treatment) the cultured medium 
was collected from both dishes and fresh DMEM was re-added to each condition. 48 hours later 
(144 hours after the initial α-syn treatment) the cultured medium was collected for the final 
time. The cultured media was then centrifuged at 1200g for 5 mins, and the supernatant was 
collected. The supernatant was then added to a 24 well plate at 1mL per well, and spinoculated 
via centrifuge at 1200g, 13C for 2 hours onto cover-slips. Afterwards, the spinoculated 
supernatant was aspirated off and the cover-slips were fixed in our formaldehyde fix solution. 
Cover-slips were then treated with one of the respective primary antibodies: no treatment, CD9, 
CD63, CD81, or LAMP1 for 1 hour. Afterwards, cover-slips were treated with their respective 
Alexa 647 conjugated secondary antibody for 20 minutes. Cover-slips were then imaged by 
wide-field microscopy with each condition being imaged 25-30 times.  Afterwards, images were 
deconvolved and then analyzed by Imaris software from Bitplane.  A spots algorithm was then 
created to analyze the either the S15 or the α-syn channel, respectively.  The maximum 
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fluorescent intensity of the respective other channels were then plotted in GraphPad Prism 
version 6 as an X&Y scatter plot.  The above background analyses used to find above background 
levels for each channel were done in Microsoft Excel. 
Results 
In order to use fluorescence microscopy, we created a stable SH-SY5Y cell-line that 
expresses our S15 mCherry construct that labels plasma membranes with a mCherry 
fluorophore. This process occurs due to our constructs utilization of the first 15 amino acids of 
the proto-oncogene tyrosine-protein kinase Src (SRC) protein sequence followed by a mCherry 
fluorophore. These first 15 amino acids from SRC signal for, and undergo, a myristoylation 
reaction which results in the addition of a myristoyl (14-carbon) lipid which acts as a plasma 
membrane anchor at the N-terminal glycine (Figure 8.). Additionally, due to the large amount of 
arginines and lysines found within this 15 amino acid sequence, it is particularly positively 
charged resulting in an increased attraction to the negatively charged head groups of 
phospholipids increasing its propensity for plasma membrane association. Therefore, our S15 
mCherry construct (From here on referred to simply as S15) effectively labels our cell’s plasma 
membranes with the mCherry fluorophore resulting in red plasma membranes. Furthermore, 
and most importantly, it is also readily secreted within extracellular vesicles (Reference image of 
EVs Figure 10). 
70 
 
 
 
 
Figure 8. A cartoon version of the S15 construct myristoylation. The image shows how the S15 mCherry 
construct undergoes the addition of the myristoyl lipid anchor utilizing the first 15 amino acids from the 
SRC protein.  
 
Next to validate our methodology and assess whether our S15 SH-SY5Y cells were 
capable of taking up PFF α-syn and secreting it within exosomes, we treated our S15 cells with 
sonicated Alexa 488 labeled PFF α-syn (green).  24 hours after the treatment, the cell cultured 
medium was replaced.  72 hours after the replacement the cultured medium collected (96 hours 
since initial treatment), and was once again replaced.  The subsequently cultured medium was 
collect a second time 48 hours after the second replacement (144 hours since initial treatment).  
Afterwards the medium was spinoculated onto cover-slips and stained for our markers of 
interest.  As result of the S15 label we are able to readily determine whether our PFF α-syn is 
taken up and secreted within EVs due to the incorporation of the S15 construct, which serves as 
pan-EV marker (although it does not get incorporated into all EVs, it is readily incorporated). 
Therefore, the resulting vesicles can be identified by microscopy based on green and red 
fluorophore co-localization.  
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After PFF α-syn treatment, we collect the conditioned cultured medium and divided it 
into 1mL increments among cover-slips, followed by spinoculation, in preparation for imaging, 
as shown in Figure 9. 
 
 
Figure 9. Schematic of EV imaging methodology. The image is a graphical representation of the 
methodology used to collect and spinoculate cultured medium onto the cover-slips in order to image 
secreted EVs. Cells are transduced with the S15 mCherry construct and are either left untreated or 
treated with FitC (Green) labeled PFF α-syn.  24 hours later the medium was changed. 72 hours after the 
medium change the cultured medium was collected and medium was replaced. 48 hours after the second 
medium change the cultured medium was collected again.  The cultured medium was centrifuged at 
1200g, for 5 minutes, at 13
o
C and supernatant was collected. The supernatant was then separated into 
1mL intervals and spinoculated onto cover-slips at 1200g, for 2 hours, at 13
o
C. Afterwards respective 
cover-slips were fixed and then stained for LAMP1, CD9, CD63, CD81 or 2
o
 only with respect to the 
replicate.  This was replicated a total of 3 separate times with two time points results being analyzed as 
part of each replicate. 
The cover-slips were then stained respectively for CD9, CD63, or CD81, from the tetraspanin 
family, to identify if our PFF α-syn was found within the exosomal subpopulation of total EVs, as 
these proteins represent canonically accepted exosomal markers.  Furthermore, we choose to 
also stain for the lysosomal associated membrane protein 1 (LAMP1 or CD107a), another 
transmembrane protein commonly associated with exosomes but also found within lysosomes. 
After staining for the exosomal marker of choice, we imaged our cover-slips by wide-field 
deconvolution microscopy; a representative image is shown of our extracellular vesicles on a 
cover-slip (Figure 10). 
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Figure 10. Representative example of triple co-localization. The panel shows a representative example of 
triple co-localization of all three channels. Each image of the panel indicates its associated color channel 
and as well as a merge image of all the channels being displayed as one image. Triple co-localization 
events are denoted by the arrow and mark the location the in each separate image, as well as, the merge.  
The resulting images taken by our microscope were then analyzed by the Imaris imaging 
software. Imaris allows for analysis of EVs by creating a spots algorithm around the 
immunofluorescent channel of interest through the use of creating a puncta specific mask which 
will be referred to as a spot.  We began by building our spot’s algorithm around our S15 
mCherry channel shown in Figure 11, depicted as a gray orb and our S15 mcherry construct is 
shown in red. The spots algorithm, which is specifically designed by Bitplane for analyzing 
puncta, allows one to look at the fluorescence intensity of all the fluorescent channels one uses 
within any specific spot.  Therefore by building a spots algorithm around our S15 puncta, the red 
channel, we were then able to analyze the fluorescence intensity of our other fluorescent 
channels within each spot. IE, the fluorescence intensity of the green or far-red channel found 
within our S15 red spots. 
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 Afterwards, we exported our S15 spots algorithm to the Imaris batch coordinator tool, 
where the algorithm we created was extrapolated to all of our images and subsequently all 
replicates. This process allows for an unbiased, high-throughput analysis of all our images to 
identify all spots based on our established criteria. Additionally, the batch coordinator gives us 
an organized numerical value (among other things) of the max fluorescence intensity of the each 
fluorescent channels for every spot among all images. The max fluorescence intensity of our PFF 
α-syn and antibody stain was then plotted against one another on an X&Y scatter plot for co-
localization analysis. Within the scatterplot each point represents a S15 positive spot; where the 
X-value is the green channel intensity, either representing background noise or PFF α-syn 
fluorescence intensity depending on the treatment condition; and where the Y-value is the 
respective antibody stained protein intensity.  Additionally, the individual axes are shown at a 
log2 scale to account for microscopy bit rate, resulting in a less congested and more linear 
representation of their relationship (Figure 12, A-E). 
The above background threshold, indicating that an S15 spot was positive for a 
respective channel, was formulated by taking the background levels of each channels control 
condition, α-syn PFF vs. untreated and respective antibody staining to the secondary only 
control, and then calculating the average and the standard deviation of the intensity value for 
each channel, respectively.  The respective average was then added to 2x the standard deviation 
of the same respective channel’s control (control channel: μ + 2σ).  IE the above background, 
indicating positive co-localization of α-syn, was established by identified the average plus 2x the 
standard deviation of the intensity of the green channel within the S15 spots of the untreated 
cells (μ + 2σ).  
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Figure 11. Representative image from a cover-slip of spot algorithm built around the S15 construct. The 
S15 mCherry construct is shown in red while the gray indicates where a spot is made around the S15 
signal. The left image shows a S15 mCherry channel alone. The right image shows a merge of the S15 
mCherry channel with the S15 Spots algorithm. 
 
As evidence of our above background methodology, the corresponding S15 spots co-
localization graph for the α-syn untreated condition, in which the cover-slip were stained with 
the secondary only antibody is shown in Figure 12, A, indicating that minimal positive co-
localization, shown as percentage, occurs within its S15 spots, as one would expect.  
Representative images of S15 co-localization graphs are provided for the PFF α-syn 
treatment condition, in which each graph shows co-localization for each respective antibody 
stains.  The same process was done for the α-syn untreated condition (not shown). This process 
was repeated 3 times, in which each replicate represents 2 collections, resulting in a total of 6 
co-localization analyses for each antibody stain among the untreated and PFF α-syn treated 
conditions (Except for LAMP1 staining which was replicated 3 times with 2 collections per 1 
replicate and 1 collection for 2 replicates, resulting in 4 measurements of which 3 independent 
experimental replicates occurred). 
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Figure 12. Representative co-localization analysis scatter plot of S15 spots on an individual cover-slip 
and its respective antibody stain. The figure shows the co-localization analysis scatter plot for the third 
replicates 96-144hr (second time point). The percentage shown in each quadrant indicates the amount of 
S15 spots that co-localize with the S15 and/or the antibody stain and PFF α-syn. Each quadrant 
percentage is shown adjacently. Quadrants consist of: positive for S15 and PFF α-syn (bottom right 
quadrant of any individual graph); positive for S15 and the respective antibody stain, indicated by the title 
(top left quadrant of any individual graph); Triple positive for S15, PFF α-syn, and the respective antibody 
stain (top right quadrant of any individual graph); or finally, S15 only (bottom left quadrant of any 
individual graph). Each stain was performed between 4-6 times on individual cover-slips with 20-25 
images taken per cover-slip.   
76 
 
 
 
 
 Figure 13. Summation each respective antibody stain’s S15 spots co-localization data for all of α-syn 
PFF treated cells. The figure shows summation of each antibody stain’s replicates and time points with 
respect to the quadrants identified in Figure 12. Each stain has 3 total data replicates with 2 time points 
being analyzed except for LAMP1 which has 3 replicates with only the third replicate having both time 
points. Error bars show the standard error of the mean. 
The summation of these analyses are shown in Figure 13 where each of the quadrants 
are broken down into one of the four possibilities and the percentage of the total S15 positive 
spots for each treatment and each antibody stain are shown: S15 only (negative for α-syn and 
the respectively indicated antibody stain); S15 & α-syn positive (Positive for S15 and α-syn but 
negative for the respective antibody stain); S15 & Antibody positive (positive for S15 and the 
respective antibody stain but negative for α-syn); or Triple positive (S15 positive, α-syn positive, 
and positive for respective antibody stain). 
77 
 
 
 
 
Figure 14. Summation of S15 spots positive for the respective antibody stains among untreated and α-
syn PFF cells secreted EVs. The figure shows summation of each antibody stain’s replicates and time 
points with respect to the S15 & Ab stain and the Triple positive quadrants of the S15 spots shown in 
Figure 12 & 13.  Error bars show the standard error of the mean. 
Based on our summations we found that our S15 construct co-localizes preferentially 
with CD81 and CD63 in both are untreated and PFF treated conditions while CD9 and LAMP1 co-
localize substantially less.  Interestingly, we found that the percent co-localization between our 
S15 positive spots resulted in similar levels of stain co-localization regardless of the α-syn 
treatment condition, as shown in Figure 14. Also, we found that S15 and α-syn co-localized at a 
low percentage among all our S15 spots regardless of stain, likely due to a low incorporation 
within EVs. However, when it was incorporated into S15 positive vesicle it was also seemingly 
always positive for CD81, and was likely positive for either CD63 or LAMP1, based comparing the 
percentages between the Figure 13, A-E.  
 
78 
 
 
 
 
 Figure 15. S15 spots identified by the Imaris spots algorith per image. The figure shows the average 
amount of S15 positive spots identified among all cover-slips. All time points from each cover slip 
regardless of stain were pooled. The average amount of S15 mCherry spots created per image from the 
supernatant from both α-syn treated and untreated S15 SY5Y cells are compared against one another. 
Student’s T-test was conducted, p <.001. The error bars show the standard error of the mean.  
In addition to creating co-localization analyses, we were also able to assess the number 
of S15 spots per cover-slip among our treatment conditions.  This allowed us to get a relative 
sample measurent of total EV’s being secreted among our untreated and α-syn PFF treatment 
conditions. We pooled images among replicates and then averaged the amount of S15 spots 
from each image among all antibody staining paradigms, to compare how α-syn PFF’s influenced 
total EV secretion. We found that there was a significantly greater amount of S15 spots in our α-
syn PFF condition when compared to untreated (Figure 15).   
Next, due to the low percent of α-syn PFFs observed within the S15 positive spots, we 
chose to build a new algorithm around the α-syn channel to better characterize what 
extracellular markers α-syn co-localizes with and verify that α-syn was being secreted in 
association with S15 positive EVs. To do this, we simply built a spots algorithm around α-syn and 
plotted the batched coordinator results in a similar fashion as the S15 positive spots (Figure 16). 
79 
 
 
 
However, the X-axis for the α-syn spots was replaced with S15 channel intensity.  Representative 
co-localization graphs for the respective antibody stains are shown in Figure 16. The summation 
of all replicates is shown in Figure 17.  The antibody staining above background threshold was 
already established by our S15 spot algorithm and the same value was used. The above 
background for the S15 was established via visual observation of images comparing areas where 
no puncta of any location was observed and by using our intensity threshold used within our S15 
Spots algorithm.  
As indicated in Figure 17, A-E, the majority of α-syn spots that were positive for S15 
were also positive CD81 the largest amount of time among our antibody stains. In contrast, CD9 
was negative for S15 positive, α-syn spots a large percentage of the time; While, the S15 
positive, α-syn spots, were roughly found to be positive and negative for CD63 and LAMP1 in 
roughly equal ratios. 
 Interestingly, a percentage of α-syn is not positive for S15, which may indicate that PFF 
α-syn is not contained with an extracellular vesicle, was not taken up into cells, or is contained 
within an EV without the S15 construct. Regardless of the scenario, we found that the majority 
of our PFFs co-localized with our S15 construct at roughly ~65% (Secondary only, α-syn spots, 
S15 positive, Figure 17, A) indicating that PFFs may be preferentially associated with EVs.   
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Figure 16. Representative co-localization analysis scatter plot of α-syn PFF spots on individual cover slip 
and its respective antibody stain. The figure shows the co-localization analysis scatter plot for the third 
replicates 96-144hr (second time point). The percentage shown in each quadrant indicates the amount of 
α-syn PFF spots that co-localize with the α-syn PFF spots and/or the antibody stain and S15 mCherry. Each 
quadrant percentage is shown adjacently. Quadrants consist of: positive for S15 and PFF α-syn (bottom 
right quadrant of any individual graph); positive for α-syn PFF spots and the respective antibody stain, 
indicated by the title (top left quadrant of any individual graph); Triple positive for S15, PFF α-syn, and the 
respective antibody stain (top right quadrant of any individual graph); or finally, α-syn PFF spots only 
(bottom left quadrant of any individual graph). Each stain was performed between 4-6 times on individual 
cover-slips with 20-25 images taken per cover-slip.   
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Figure 17. Summation of α-syn PFF spots identified for each respective antibody stain’s co-localization 
data. The figure shows summation of each antibody stain’s replicates and time points with respect to the 
quadrants identified in Figure 12. Each stain has 3 total data replicates with 2 time points being analyzed 
except for LAMP1 which has 3 replicates with only the third replicate having both time points. Error bars 
show the standard error of the mean. 
 
Discussion 
The goal of study was to create a methodology for single EV analysis. As a part of our 
investigation of α-syn secretion we wanted to analyze which EVs PFF α-syn associates with in an 
attempt to better understand the processes associated with α-syn secretion.  The implication 
being that secreted misfolded α-syn may be contained within specific EVs and the proteins 
associated within these EVs may better explain the mechanisms associated with its secretion.  
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Due to the majority of researchers utilizing techniques, such as Western Blot, ELISA or 
immunoblot, to analyze the entirety of the EV population in association with the vesicles 
containing α-syn, we developed methodology that allows us to assess the only vesicles that 
contain the immunofluorescent marker of our choice.  This process allows for specific analysis of 
only the EVs we are interested in which is particularly important due a growing body of evidence 
suggesting that EVs are heterogeneous with specific vesicular subsets existing within the 
entirety of the total EV populations. By using deconvolution microscopy combined with imaging 
software, we are able to analyze vesicles on an individual basis without the assumption of all 
vesicles being the same. 
As part of our validation process we found that our S15 construct, which we used as a 
pan-EV marker, was positively associated with CD81 a majority of the time and that CD63 was 
also found associated a little over 50% of the time. In contrast, CD9 and LAMP1 were found to 
be positively associated with S15 a much lower percentage of the time.  We found that PFF α-
syn treatment did not impact the percent S15 spots positive for our respective antibody stains 
(CD9, CD63, CD81, or LAMP1) when compared to our control untreated (Figure 14, A&B). 
However, an unexpected observation was made when the average number of S15 spots was 
quantified. The PFF α-syn treated had significantly more S15 positive spots, when compare to 
the untreated control (Figure 15), despite the stain distribution remaining constant between the 
untreated and PFF treatment condition. Additionally, when we built an α-syn PFF spots 
algorithm our results indicate that α-syn associated with our S15 construct ~65% of time, these 
results indicate that pathological α-syn, represented by our PFFs, are more highly associated 
with our EVs.  Furthermore, our α-syn PFF spots showed that the majority of the EV markers we 
stained for were positive for both α-syn and S15 in roughly similar percentages as their positive 
S15 co-localization percentage (S15 spots, Antibody positive staining percent Figure 13, A-F). 
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Except for LAMP1, which was particularly interesting, as based on our results extracellular PFF α-
syn is EV positive ~65% of time (based on our secondary only, S15 positive, α-syn spots, Figure 
17, A).  When these PFFs are associated with an EV, they are also positive for LAMP1 ~30% of 
the time (α-syn spots, triple co-localization, LAMP1 staining, Figure 17, E). However, LAMP1 
positive vesicles only make up ~%20 of the total secreted EV population (as indicated by our S15 
spots, positive for LAMP1, Figure 13, E & Figure 14). Therefore, when PFF α-syn is found within 
an EV, roughly 45% of the time it will be found within a known specific subpopulation of EVs that 
only represent 20% of the total population.  Furthermore, this EV population is of known 
lysosomal origin. These conclusions support the canonically accepted idea that lysosomal 
dysfunction is associated with PD pathology.  
Future Directions 
The authentication of this methodology provides an opportunity to investigate the EVs 
released from any set of cells.  Rather than using the S15 marker one could use a fluorescent 
dye that stains plasma membranes if one wanted to look at WT cells which would allow for 
more flexibility. Realistically, this methodology opens up a large amount of possibilities for 
anyone interested in studying EVs from any type of cells and any type of disease state. Within 
the context of our PD research, one possible angle we would like to pursue is to analyze the EVs 
released from our α-syn DSP cell using the GFP signal with the addition of autophagic drugs, and 
the LAMP1 marker and other overlapping endo-lysosomal and autophagic proteins, such as the 
galectin proteins. Utilizing this methodology we could identify how autophagic processes 
influenced the vesicular portion of DSP secretion and whether specific autophagic processes are 
associated with differences in specific subtypes of exosomes. 
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CHAPTER SIX: 
CONCLUSIONS 
The secretion of misfolded α-syn provides a clear way to potentionally explain how the 
transmission of disease pathology could be occurring within the brains of individuals with 
synucleinopathies. In support of this idea, the results of others, as well as, the work conducted 
in this thesis shows that rotenone, a pesticide that is heavily linked to increasing PD onset, 
increases α-syn secretion, including non-monomeric variants [222].  These results provide one 
example, among a body of evidence that indicates that secretion is likely linked to spreading 
synucleinopathy pathology. In further support, the dyregulation of autophagic mechanisms may 
further exacerbate pathology, as reviewed earlier, several PD associated genes play a role in 
regulating autophagy, vesicular trafficking, and α-syn release, including LRRK2 and ATP 13A2. 
While the secretion of α-syn may increase the spreading of the diseased state from cell-to-cell, it 
is unclear whether on an individual cell basis if the secretory process is inherently negative as it 
represents another method of removal of α-syn aggregates. Hypothetically, sharing the 
degradative burden of α-syn aggregates among cells may be protective in comparison to one 
cell attempting and failing to degrade all misfolded α-syn.  In addition, evidence exists for both 
sides of the argument on whether individual cell secretion of α-syn is detrimental or favorable 
and it is likely that both are true depending on the circumstance.  
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ATP 13A2 mutations are associated with familial PD and exhibit a cellular phenotype 
characterized by dysregulation of endosomal and autophagic cargo sorting [88-89]. However, 
over-expression of WT ATP 13A2 increases neuronal survivability, and results in decreased α-syn 
accumulation but increased exosomal α-syn secretion [88-89]. Additionally, higher levels of ATP 
13A2 mRNA are found within the surviving neurons of individuals with PD [91].  Therefore, these 
results indicate that increased α-syn secretion is important for cell survival. 
A similar paradigm was found when we investigated the secretion of our α-syn DSP 
construct within chapter 4. We found that increasing autophagic activity through both mTOR 
independent and dependent pathways as a result of trehalose and rapamycin treatment, 
respectively, increased the secretion of our α-syn DSP construct.  Additionally, while we did not 
investigate α-syn aggregate clearance, others have found that trehalose or rapamycin treatment 
is associated with decreased α-syn aggregate accumulation, and lower levels of cell death [9]. 
These results further support the idea that increased secretion of α-syn may also be tied to its 
removal. In addition, these results implicate autophagy as being a potential pathway for 
increasing both clearance, as well as, secretion of α-syn. Therefore, increased autophagic 
activity increases cell survivability but comes at the cost of increased α-syn secretion. 
Interestingly this paradigm, that autophagy is responsible for both the removal of 
aggregate α-syn, as well as, its secretion and is subsequently linked to cell survivability, is also 
shared among another neurodegenerative disease associated protein, Aβ. When Aβ transgenic 
mice were given an ATG7 neuron specific knock-out, it was found that Aβ secretion was 
decreased but was also increased Aβ accumulation within the perinuclear regions of the mice 
[99]. While these mice experienced less Aβ secretion, these mice were shown to have decreased 
life spans and exacerbation of a neurodegenerative phenotype.  
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Similar to the cellular level results mentioned in the previous Aβ study, we found that 
when our respective ATG7 and Beclin-1 knock-out cells were treated with bafilomycin-A1, a 
decreased level of non-monomeric α-syn secretion occurred. Furthermore, similar results were 
recapitulated by Ejlerskov et al., 2013, where they showed that siRNA mediated knock-down of 
ATG5 substantially decreased α-syn secretion. Therefore, while decreased secretion of either Aβ 
or α-syn may seemingly indicate a lower potential for transferring disease pathology which 
occurred as result of depletion of essential autophagic proteins, within the context of Aβ it 
resulted in an exacerbation of the disease phenotype and decreased life span within mice. 
Finally, the clearance of α-syn can also result in a differing paradigm as a result of 
decreased proteasome activity. Several studies have shown that when the 26S proteasome is 
inhibited, an upregulation of autophagic activity occurs in attempt to compensate [213-218]. 
This process was shown by us and others to cause an increase in α-syn secretion. However, 26S 
proteasome inhibition is also linked to an increase in α-syn accumulation, likely due to the loss 
of function in general protein clearance that no longer occurs as the UPS also is important for 
the degradation of α-syn aggregates [196-197]. Therefore, inhibition of the proteasome results 
in aggregation of α-syn, suggesting intracellular PD pathology, while potentially also 
exacerbating the cell-to-cell transfer of pathology due to increases in secretion. 
Our demonstration of single EV analysis methodology indicated that extracellular PFF α-
syn, representing a pathological α-syn variant, was found in low levels within the extracellular 
environment. However, when it was found in the extracellular environment it was associated 
with an EV the majority of the time (~65%).  Additionally, these PFF α-syn positive EVs were also 
positive for the LAMP1 marker ~30%, a marker that was found in only ~20% of our total EV 
population.  These data indicates that pathological α-syn EVs may originate from the lysosome, 
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which supports the axiomatically accepted hypothesis that lysosome dysfunction is central to PD 
pathology.   
In further support of exosomes being tied to lysosomal dysfunction, several studies have 
linked oligomeric α-syn secretion to lysosome dysfunction.  Bafilomycin-A1 treatment, which 
inhibits lysosome acidification, has been shown to increase both general α-syn, as well as, 
exosome specific α-syn secretion [8-9, 49, 88].  Furthermore, studies looking at bafilomycin-A1 
treatment also provide a link that intersects both exosome secretion and autophagy. As 
bafilomycin-A1 treatment has also been shown to increase autophagosome accumulation as 
well as α-syn secretion through autophagic mechanisms [9, 49].  This is further supported by our 
findings, showed within our autophagic mechanisms influence the unconventional secretion of 
non-monomeric α-syn, that bafilomycin-A1 increased secretion our complemented α-syn DSP 
construct and that this secretion decreased significantly when we genetically depleted either 
autophagic proteins ATG7 or Beclin-1 via CRISPR-CAS9 knock-out. However, whether this 
influences the exosomal portion of α-syn secretion still needs to be investigated but may 
provide a link to autophagic inhibition and α-syn associated exosomes.  
The secretion of misfolded α-syn represents a very clear way in which the spreading of 
synucleinopathy pathology can be transmitted between cells, resulting in further propagation. In 
this document we have demonstrated that non-monomeric α-syn secretion is linked to 
autophagic mechanisms and dysregulation can have profound effects on the levels at which it is 
secreted.  Our data shows that specific activators and inhibitors could differentially change the 
secretion of our non-monomeric α-syn DSP construct.  Additionally we provided evidence 
through chemical and genetic evidence that autophagic proteins are important to α-syn 
secretion; as genetically depleted either autophagic proteins ATG7 or Beclin-1 via CRISPR-CAS9 
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knock-out significantly reduced non-monomeric α-syn secretion within the context of 
bafilomycin-A1 treatment.  This demonstration, through bafilomycin-A1 treatment, is 
particularly interesting and it serves as bridge: In the cell bafilomycin-A1 reduces the 
acidification of lysosomes, a process that results in autophagosome accumulation and 
degraditive dysfunction but also increases both non-vesicular and exosome specific α-syn 
secretion. In this thesis, within THE NOVEL CHARACTERIZATION OF PREFORMED FIBRILLIAR 
ALPHA-SYNUCLEIN’S ASSOCIATION WITH EXTRACELLULAR CELLULAR VESICLES ON A SINGLE 
VESICLE LEVEL, we found that pathological α-syn species were often found within EVs that were 
often associated with lysosomal markers, demonstrating an intersection between exosomes, 
autophagy, and lysosomal dysfunction. However, familial PD pathology also provides a strong 
genetic tie for lysosomal dysregulation role in PD [77-84, 91].  As reviewed earlier, specific PD 
associated genes such as LRRK2 and ATP 13A2 play overlapping in roles in affecting autophagy, 
vesicular trafficking, and α-syn release. However, it is unclear whether on an individual cellular 
basis if this process is inherently negative as it represents another method of removal of α-syn 
aggregates. Additionally, the sharing of the degradative burden of protein aggregates, such as α-
syn, among cells may actually be protective against disease propagation in some instances.  
Evidence exists for both arguments on whether α-syn secretion is detrimental or favorable and 
it is likely that both are true depending on the circumstance. 
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APPENDIX A 
AUTOPHAGIC PATHWAY FIGURE 
Figure 18. Autophagic pathway. Depicted in the figure is a cartoon flow-map of the autophagic pathway. 
Starting from left-to-right the figure shows how either mTOR1 or AMPK can respectively inhibit or activate 
ULK1 from the ULK complex resulting in the inhibition or initiation of autophagy.  Activation of autophagy 
results in the activation of the Beclin and ULK Complex. Their respective activations induces the isolation 
of a section of double membrane phospholipid bilayer that develops into the autophagophore, becoming 
enriched in ATG proteins, and the formation of PI3KC3, subsequently increasing PI3P concentrations. The 
autophagophore then goes through elongation which is driven by the by the ATG Complexes resulting in 
the processing and translocation of LC3 to the autophagophore. The autophagophore continues through 
elongation until it becomes the autophagosome, an enclosed double-membrane compartment. The 
autophagosome can either fuse with the late endosome to form the amphisome or directly go through 
the degradative or secretory pathway. The degradative pathway results in lysosome fusion resulting in the 
breakdown of autophagosome or amphisome cargo. In contrast, the secretory pathway results in the 
plasma-membrane fusion and release of autophagosome or amphisome cargo into the extracellular 
space.  
 
